<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6032224</article-id><article-id pub-id-type="doi">10.3390/ijms19061781</article-id><article-id pub-id-type="publisher-id">ijms-19-01781</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Annexins in Translational Research: Hidden Treasures to Be Found</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schloer</surname><given-names>Sebastian</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pajonczyk</surname><given-names>Denise</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rescher</surname><given-names>Ursula</given-names></name><xref rid="c1-ijms-19-01781" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-ijms-19-01781">Institute of Medical Biochemistry, Centre for Molecular Biology of Inflammation, University of Muenster, Von-Esmarch-Street 56, D-48149 Muenster, Germany; <email>sebastschl@gmx.de</email> (S.S.); <email>Denise.Pajonczyk@ukmuenster.de</email> (D.P.)</aff><author-notes><corresp id="c1-ijms-19-01781"><label>*</label>Correspondence: <email>rescher@uni-muenster.de</email>; Tel.: +49-251-83-52121</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2018</year></pub-date><volume>19</volume><issue>6</issue><elocation-id>1781</elocation-id><history><date date-type="received"><day>25</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>12</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The vertebrate annexin superfamily (AnxA) consists of 12 members of a calcium (Ca<sup>2+</sup>) and phospholipid binding protein family which share a high structural homology. In keeping with this hallmark feature, annexins have been implicated in the Ca<sup>2+</sup>-controlled regulation of a broad range of membrane events. In this review, we identify and discuss several themes of annexin actions that hold a potential therapeutic value, namely, the regulation of the immune response and the control of tissue homeostasis, and that repeatedly surface in the annexin activity profile. Our aim is to identify and discuss those annexin properties which might be exploited from a translational science and specifically, a clinical point of view.</p></abstract><kwd-group><kwd>annexins</kwd><kwd>inflammation</kwd><kwd>host-pathogen interplay</kwd><kwd>drug target</kwd><kwd>translational research</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-19-01781"><title>1. Introduction</title><p>Annexins stepped into the light in 1978, when a soluble protein was isolated from bovine adrenal glands that caused the aggregation of secretory vesicles in vitro when free Ca<sup>2+</sup> was present [<xref rid="B1-ijms-19-01781" ref-type="bibr">1</xref>]. This protein, initially called &#x0201c;synexin&#x0201d;, turned out to be the first discovered member of a new protein family, the annexins [<xref rid="B2-ijms-19-01781" ref-type="bibr">2</xref>]. The Ca<sup>2+</sup>-dependent binding to phospholipid-containing membranes turned out to be their hallmark, mediated by their signature feature, the annexin repeat. More than 500 different members of the superfamily have now been identified [<xref rid="B3-ijms-19-01781" ref-type="bibr">3</xref>]. According to the official nomenclature proposed in 1999, the 12 annexins commonly found in vertebrates constitute the A subclass [<xref rid="B4-ijms-19-01781" ref-type="bibr">4</xref>]. Structurally, annexins all share the characteristic and highly conserved &#x0201c;core&#x0201d; domain, usually made up of four annexin repeats, each of which typically contains a Ca<sup>2+</sup>-binding motif and mediates the specific binding to negatively charged phospholipids. In 1990, the first crystal structure (of AnxA5) confirmed the predictions [<xref rid="B5-ijms-19-01781" ref-type="bibr">5</xref>]. The tightly packed and slightly convex annexin core domain is linked to an N-terminal part (sometimes also called the &#x0201c;head&#x0201d; or &#x0201c;tail&#x0201d; domain) that is unique for a given annexin. N-terminal tails are surprisingly diverse in length and sequence, and sometimes contain binding sites for interaction partners, including members of the S100 family of EF-hand-containing Ca<sup>2+</sup>-binding proteins [<xref rid="B6-ijms-19-01781" ref-type="bibr">6</xref>]. In several annexins, the tail is a substrate for kinases that have a strong influence on a wide variety of signal pathways, such as the proto-oncogene tyrosine-kinase Src and the Ca<sup>2+</sup>-controlled serine-threonine kinase PKC [<xref rid="B7-ijms-19-01781" ref-type="bibr">7</xref>,<xref rid="B8-ijms-19-01781" ref-type="bibr">8</xref>,<xref rid="B9-ijms-19-01781" ref-type="bibr">9</xref>]. Phosphorylation is thought to regulate the protein function [<xref rid="B5-ijms-19-01781" ref-type="bibr">5</xref>,<xref rid="B10-ijms-19-01781" ref-type="bibr">10</xref>] and has been reported to control secretion, at least in the case of AnxA1 and A2, through a yet unknown unconventional pathway of these otherwise cytosolic proteins [<xref rid="B11-ijms-19-01781" ref-type="bibr">11</xref>,<xref rid="B12-ijms-19-01781" ref-type="bibr">12</xref>,<xref rid="B13-ijms-19-01781" ref-type="bibr">13</xref>,<xref rid="B14-ijms-19-01781" ref-type="bibr">14</xref>,<xref rid="B15-ijms-19-01781" ref-type="bibr">15</xref>]. Not surprisingly, annexins have been implicated in the regulation of a broad range of cellular and physiological processes that are linked to cellular membranes, such as vesicle organization, membrane trafficking and scaffolding, endo- and exocytosis, and membrane/cytoskeleton interactions [<xref rid="B16-ijms-19-01781" ref-type="bibr">16</xref>,<xref rid="B17-ijms-19-01781" ref-type="bibr">17</xref>,<xref rid="B18-ijms-19-01781" ref-type="bibr">18</xref>,<xref rid="B19-ijms-19-01781" ref-type="bibr">19</xref>,<xref rid="B20-ijms-19-01781" ref-type="bibr">20</xref>,<xref rid="B21-ijms-19-01781" ref-type="bibr">21</xref>]. Membrane dynamics is also a recurrent theme in host&#x02013;pathogen interactions, and annexins might function as host cell-derived auxiliary proteins in shaping the microbe&#x02013;host interplay [<xref rid="B22-ijms-19-01781" ref-type="bibr">22</xref>]. In recent years, a growing number of annexin knock out (KO) mouse models have been constructed [<xref rid="B23-ijms-19-01781" ref-type="bibr">23</xref>], and they will certainly prove to be useful tools for investigating annexin functions, both as drugs and therapeutic targets.</p></sec><sec id="sec2-ijms-19-01781"><title>2. Extracellular Functions&#x02014;Detection of Phosphatidylserine and Immuno-Evasion</title><p>During pathophysiological responses, typical changes in the membrane composition and loss of membrane asymmetry are repeatedly observed. A prominent feature is the translocation of phosphatidylserine (PS), which in viable cells is located in the cytosol-facing leaflet of the plasma membrane, to the outside-facing leaflet of the apoptotic cell membrane [<xref rid="B24-ijms-19-01781" ref-type="bibr">24</xref>]. In the presence of Ca<sup>2+</sup>, PS is a high-affinity ligand for the annexins and Ca<sup>2+</sup>-dependent PS binding is in fact, a defining trait of the annexin family [<xref rid="B25-ijms-19-01781" ref-type="bibr">25</xref>]. For AnxA5, a <italic>K<sub>D</sub></italic> value of 5 &#x000d7; 10<sup>&#x02212;10</sup> in the presence of Ca<sup>2+</sup> [<xref rid="B26-ijms-19-01781" ref-type="bibr">26</xref>] underscores the high selectivity in its preference for PS over other negatively charged phospholipids, and this specificity is the reason behind the wide use of labelled AnxA5 for the identification of apoptotic cells [<xref rid="B27-ijms-19-01781" ref-type="bibr">27</xref>], for example in flow cytometry applications [<xref rid="B28-ijms-19-01781" ref-type="bibr">28</xref>,<xref rid="B29-ijms-19-01781" ref-type="bibr">29</xref>].</p><p>The surface-exposed PS assists in the recognition and subsequent phagocytic engulfment, of dying cells [<xref rid="B30-ijms-19-01781" ref-type="bibr">30</xref>]. This process is called efferocytosis and is immune-calming in its nature [<xref rid="B30-ijms-19-01781" ref-type="bibr">30</xref>] and seems to depend on the concomitant externalization of AnxA1 [<xref rid="B31-ijms-19-01781" ref-type="bibr">31</xref>], which is part of the apoptotic cell-associated molecular patterns (ACAMPs) [<xref rid="B32-ijms-19-01781" ref-type="bibr">32</xref>] that is presented by dying cells and conveys the switch towards an anti-inflammatory response. In accordance with the function as an &#x0201c;eat-me&#x0201d; signal, which most likely includes the acquisition of PS-bound anxA1 on the outer surface, phagocytosis of PS-decorated red blood cells is inhibited when PS is masked [<xref rid="B33-ijms-19-01781" ref-type="bibr">33</xref>], for example through PS-binding proteins. Recent findings suggest that exposition of PS on the outer leaflet is not confined to apoptosis but appears to act as an evolutionary conserved global immunosuppressive signal [<xref rid="B34-ijms-19-01781" ref-type="bibr">34</xref>], and is also found on the surface of cancer cells [<xref rid="B35-ijms-19-01781" ref-type="bibr">35</xref>]. Unfortunately, in this context, PS exposure is not linked to cell elimination but seems to function in immune evasion [<xref rid="B34-ijms-19-01781" ref-type="bibr">34</xref>], which, like in apoptotic cells, might depend on cell surface associated AnxA1 [<xref rid="B36-ijms-19-01781" ref-type="bibr">36</xref>]. Blocking of PS with AnxA5 might be a strategy to antagonize the immune-suppression and help establish an anti-tumor immune reaction. Furthermore, AnxA5 might be used for the development of selective molecular imaging probes for cancer diagnosis and disease management [<xref rid="B29-ijms-19-01781" ref-type="bibr">29</xref>,<xref rid="B37-ijms-19-01781" ref-type="bibr">37</xref>] and importantly, for targeting drugs to the cancer cells [<xref rid="B25-ijms-19-01781" ref-type="bibr">25</xref>,<xref rid="B35-ijms-19-01781" ref-type="bibr">35</xref>].</p></sec><sec id="sec3-ijms-19-01781"><title>3. Extracellular Functions&#x02014;Annexins and Coagulation</title><p>Exposure of PS is also an important step in the regulation of blood clotting [<xref rid="B38-ijms-19-01781" ref-type="bibr">38</xref>]. PS on the surface of endothelial cells or membrane vesicles derived from activated platelets greatly enhances the pro-thrombin/thrombin conversion which is a central unit in coagulation [<xref rid="B39-ijms-19-01781" ref-type="bibr">39</xref>]. Annexin A5 is abundantly found on the surface of the syncytiotrophoblast, which covers the placental surface, and the AnxA5 layer is considered to protect the placenta from abnormal coagulation [<xref rid="B40-ijms-19-01781" ref-type="bibr">40</xref>]. Furthermore, a polymorphism in the <italic>AnxA5</italic> gene was found to be associated with recurrent pregnancy loss. Women with the SNP in the <italic>AnxA5</italic> gene had a significantly higher risk of fetal loss than non-carriers [<xref rid="B41-ijms-19-01781" ref-type="bibr">41</xref>]. The AnxA5 anticoagulant function might depend on its well-established property to self-assemble on PS-containing membranes into an extensive two-dimensional crystal lattice [<xref rid="B42-ijms-19-01781" ref-type="bibr">42</xref>] that hinders the assembly of the pro-coagulant complexes. In line with such protective function in the blood clotting regulation, anti-AnxA5 autoantibodies are found in patients suffering from anti-phospholipid syndrome [<xref rid="B43-ijms-19-01781" ref-type="bibr">43</xref>], a disease that manifests clinically as recurrent thrombotic events and is associated with fetal loss [<xref rid="B44-ijms-19-01781" ref-type="bibr">44</xref>]. The occurrence of AnxA5 autoantibodies is also linked to autoimmune disorders [<xref rid="B45-ijms-19-01781" ref-type="bibr">45</xref>,<xref rid="B46-ijms-19-01781" ref-type="bibr">46</xref>] as observed in some patients suffering from multiple sclerosis or systemic lupus erythematosus. The current therapeutic strategy is long-term oral anticoagulation. Here, AnxA5 could be used to selectively neutralize the pathologic AnxA5 autoantibodies in vivo.</p><p>Among the many functions exerted by thrombin is the conversion of fibrinogen to fibrin which, together with platelets, forms a stable haemostatic plug that seals the injured vessel wall. To avoid excessive clot formation, the damaged endothelium slowly secrets components that assist in the conversion of plasminogen entrapped in the clot to enzymatically active plasmin, which breaks down the fibrin mesh. AnxA2, possibly as a heterotetramer together with its ligand S100A10, was demonstrated to enhance plasmin generation [<xref rid="B47-ijms-19-01781" ref-type="bibr">47</xref>,<xref rid="B48-ijms-19-01781" ref-type="bibr">48</xref>]. Consistently, AnxA2 KO mice present defective fibrinolysis and increased thrombotic vascular occlusion and impaired neovascularization [<xref rid="B49-ijms-19-01781" ref-type="bibr">49</xref>]. Blast cells of patients with acute promyelocytic leukemia (APL) express AnxA2 to a high amount [<xref rid="B50-ijms-19-01781" ref-type="bibr">50</xref>], which might explain the haemorrhagic complications observed in APL patients. In line with the impact of AnxA2 on coagulopathy [<xref rid="B50-ijms-19-01781" ref-type="bibr">50</xref>], treatment with the retinoic acid receptor ligand, all-trans retinoic acid (ATRA), attenuates AnxA2 expression and improves clinical resolution. Thus, annexin-based biologicals might serve as novel agents that open new therapeutic options and might be part of the management of such diseases in the future.</p></sec><sec id="sec4-ijms-19-01781"><title>4. Extracellular Functions&#x02014;Annexins as Ligands of Defined Inflammation-Related Receptors</title><p>A conceptually straightforward approach is to therapeutically exploit those annexins which function as endogenous ligands for known receptors. In this regard, the most prominent annexin is certainly AnxA1. Still under its former name lipocortin 1, AnxA1 gained considerable interest as a key mediator of glucocorticoid actions in inflammation. AnxA1 deficient mice do not respond to glucocorticoid treatment under inflammatory conditions [<xref rid="B51-ijms-19-01781" ref-type="bibr">51</xref>]. The full-length protein as well as its famous Ac2-26 N-terminal peptide pharmacophore, which might be proteolytically released from the full length protein [<xref rid="B32-ijms-19-01781" ref-type="bibr">32</xref>,<xref rid="B52-ijms-19-01781" ref-type="bibr">52</xref>], act in an anti-inflammatory manner in many experimental conditions, and we refer the reader to the many excellent and comprehensive review articles on that topic [<xref rid="B53-ijms-19-01781" ref-type="bibr">53</xref>,<xref rid="B54-ijms-19-01781" ref-type="bibr">54</xref>,<xref rid="B55-ijms-19-01781" ref-type="bibr">55</xref>,<xref rid="B56-ijms-19-01781" ref-type="bibr">56</xref>]. A molecular explanation was provided by the discovery that both AnxA1 and the Ac2-26 peptide specifically bind and activate the formyl-peptide receptor (FPR) subfamily [<xref rid="B57-ijms-19-01781" ref-type="bibr">57</xref>,<xref rid="B58-ijms-19-01781" ref-type="bibr">58</xref>] of heptahelical, G-protein coupled cell surface receptors. Most of the reported AnxA1 anti-inflammatory functions depend on binding to FPRs. However, it is entirely possible that additional signaling mechanisms elicited through yet unknown signalling receptors are involved, as the recognition of an annexin core (which can also be derived from annexins other than A1) also contributes to an immune-modulation [<xref rid="B59-ijms-19-01781" ref-type="bibr">59</xref>]. In humans, three members of the FPR family are found: FPR1, FPR2, and FPR3, whereas in mice at least eight FPRs are expressed [<xref rid="B60-ijms-19-01781" ref-type="bibr">60</xref>]. The most prominent receptors among the FPR family expressed in the murine model are FPR1 and FPR2 [<xref rid="B61-ijms-19-01781" ref-type="bibr">61</xref>]. FPR1 and FPR2 are predominantly expressed on the surface of many immune cells (e.g., neutrophils, macrophages, dendritic cells) but also found in endo- and epithelial cells [<xref rid="B62-ijms-19-01781" ref-type="bibr">62</xref>]. A broad range of FPR1 ligands, both agonist and antagonists, have been described [<xref rid="B63-ijms-19-01781" ref-type="bibr">63</xref>], and autocrine/paracrine signalling of externalized AnxA1 protein and/or its peptides via the FPRs might explain its well-known immune-modulatory and pro-resolving actions. Upregulation of AnxA1 expression is observed in several inflammatory conditions [<xref rid="B64-ijms-19-01781" ref-type="bibr">64</xref>] and thought to function in resolution and tissue protection [<xref rid="B65-ijms-19-01781" ref-type="bibr">65</xref>]. Indeed, studies on the use of Ac2-26-containing nanocapsules in the treatment of mucosal injury in the murine model, reported enhanced colonic wound healing, both in the acute and chronic situation [<xref rid="B66-ijms-19-01781" ref-type="bibr">66</xref>]. Interestingly, a small peptide derived from the AnxA1 N-terminus attenuated experimental colitis in mice [<xref rid="B67-ijms-19-01781" ref-type="bibr">67</xref>]. Chronic inflammation is also observed in obesity [<xref rid="B68-ijms-19-01781" ref-type="bibr">68</xref>]. Interestingly, AnxA1 KO mice on a high-fat diet are more prone to obesity than the control animals [<xref rid="B69-ijms-19-01781" ref-type="bibr">69</xref>], and FPR2 activation improved systemic insulin sensitivity [<xref rid="B70-ijms-19-01781" ref-type="bibr">70</xref>].</p><p>The AnxA1/FPR signaling axis might constitute an attractive target for the treatment of cardiovascular diseases. We only give a cursory overview as we want to draw the reader&#x02019;s attention to the excellent review articles included in this special issue &#x0201c;Annexins&#x02014;Closing the Gap between Fundamental and Translational Research&#x0201d;. A lowered AnxA1 expression in plaques obtained from patients with carotid stenosis correlates with neurological symptoms [<xref rid="B71-ijms-19-01781" ref-type="bibr">71</xref>]. Correspondingly, vulnerable plaque regions obtained from human carotid endarterectomy were shown to have less pro-resolving factors, such as resolvin D1 (RvD1), compared to more stable regions [<xref rid="B72-ijms-19-01781" ref-type="bibr">72</xref>]. RvD1 is another ligand for FPR2 [<xref rid="B73-ijms-19-01781" ref-type="bibr">73</xref>], thus indicating a potential therapeutic use of AnxA1 to support the resolution phase, suppress plaque progression, and enhance plaque stability. A growing body of evidence also points at an anti-inflammatory and neuroprotective function of AnxA1 in the brain, and AnxA1-derived molecules might emerge as promising tools in the treatment of brain diseases, including stroke and neurodegenerative disorders [<xref rid="B74-ijms-19-01781" ref-type="bibr">74</xref>,<xref rid="B75-ijms-19-01781" ref-type="bibr">75</xref>]. The decisive role of AnxA1 in stroke development and progression has been highlighted in a global murine stroke model mimicking cerebral ischemia caused by atherosclerosis, which is accompanied by cardiac arrest. Ischemic mice treated with AnxA1or the Ac2-26 peptide presented reduced infarct size, less cerebral edema, and improved neurological score [<xref rid="B76-ijms-19-01781" ref-type="bibr">76</xref>]. Furthermore, Ac2-26 prevents neutrophil-platelet aggregate formation within cerebral microvessels through the interaction with FPR2 [<xref rid="B77-ijms-19-01781" ref-type="bibr">77</xref>].</p><p>A caveat to the generalized use of AnxA1 for treatment of excess inflammatory conditions is the observation that LPS, a highly potent pro-inflammatory component derived from the bacterial wall of gram-negative bacteria, triggers the upregulation of AnxA1 expression in a variety of cell types e.g., neutrophils [<xref rid="B78-ijms-19-01781" ref-type="bibr">78</xref>]. Indeed, elevated AnxA1 plasma levels are found in 56% of septic patients after hospital admission [<xref rid="B79-ijms-19-01781" ref-type="bibr">79</xref>]. While initially beneficial [<xref rid="B78-ijms-19-01781" ref-type="bibr">78</xref>], it remains to be investigated whether excess LPS-induced AnxA1 externalization might cause the so-called endotoxin resistance, a dangerous refractive state of the innate immune system characterized by a lowered response towards a second exposure to bacterial lipopolysaccharide [<xref rid="B80-ijms-19-01781" ref-type="bibr">80</xref>]. However, the target delivery of AnxA1-derived compounds has tremendous promise to treat a range of inflammatory conditions.</p><p>AnxA2 not only impacts fibrinolysis but (in its heterotetrameric form together with S100A10) affects the Toll-like receptor (TLR) signaling. The AnxA2-S100A10 complex activates human and murine macrophages through the TLR4-MyD88 pathway, although the cell&#x02019;s responsiveness requires an additional and yet unknown factor [<xref rid="B81-ijms-19-01781" ref-type="bibr">81</xref>,<xref rid="B82-ijms-19-01781" ref-type="bibr">82</xref>,<xref rid="B83-ijms-19-01781" ref-type="bibr">83</xref>]. Signaling through the TRAM/TRIF-module of the TLR4 pathway was reported to attenuate Klebsiella-induced lung inflammation in a murine model of acute pneumonia [<xref rid="B83-ijms-19-01781" ref-type="bibr">83</xref>]. Monomeric AnxA2 was also shown to bind to and activate TLR2 via its N-terminal domain, thus assisting in the differentiation of antigen-presenting cells [<xref rid="B84-ijms-19-01781" ref-type="bibr">84</xref>]. Extracellular AnxA2 was shown to also interact with the proprotein convertase subtilisin/kexin-type 9 (PCSK9), thus interfering with PCSK9-mediated degradation of the hepatic low-density lipoprotein receptor (LDLR) [<xref rid="B85-ijms-19-01781" ref-type="bibr">85</xref>,<xref rid="B86-ijms-19-01781" ref-type="bibr">86</xref>,<xref rid="B87-ijms-19-01781" ref-type="bibr">87</xref>]. Because PCSK9 reduces the number of LDL receptors on the liver cell membrane, PCSK9 inhibitors can be used to increase the number of cell surface LDL receptors and thereby reduce cholesterol levels in the blood. Here, AnxA2 might be used as a PCSK9 inhibitor to treat hypercholesterolaemia.</p><p>In search of the molecular mechanism underlying the stimulatory effects of AnxA2 on human osteoclast formation [<xref rid="B88-ijms-19-01781" ref-type="bibr">88</xref>,<xref rid="B89-ijms-19-01781" ref-type="bibr">89</xref>], a novel type I membrane protein was identified as a putative AnxA2 receptor [<xref rid="B90-ijms-19-01781" ref-type="bibr">90</xref>]. A recent study linked a single nucleotide polymorphism (SNP) in the <italic>AnxA2</italic> gene (rs7170178) to osteonecrosis in sickle cell patients. The SNP frequency of the <italic>AnxA2</italic> gene polymorphism was higher in sickle cell osteonecrosis patients than those without osteonecrosis [<xref rid="B91-ijms-19-01781" ref-type="bibr">91</xref>]. Interaction of AnxA2 with the AnxA2 receptor also mediates adhesion and activation of the cells responsible for the initiation and maintenance of multiple myeloma [<xref rid="B92-ijms-19-01781" ref-type="bibr">92</xref>] and this signal pathway could be used as a therapeutic target.</p></sec><sec id="sec5-ijms-19-01781"><title>5. Intracellular Functions in Pathophysiological Scenarios</title><p>The following sections will cover those intracellular functions of annexins which are of potential relevance in pathophysiological scenarios. In the simplest approach, characteristic changes in the annexin expression profile might be used to diagnose and monitor diseases and to predict and evaluate therapeutic success. It is entirely possible that the relative expression levels of several annexins constitute valuable panels of biomarkers, and that such an annexin-based multibiomarker-model could be used to estimate the disease risk. Approaches addressing intracellular proteins are challenging and require sophisticated technologies that are only beginning to emerge. In this case, annexins might be used for gene and cell therapy approaches or might serve as druggable targets for cell-penetrating small molecules that interfere with or mimic annexin functions. Additionally, the intracellular delivery of annexin-derived therapeutics (e.g., as cell-penetrating fusion peptides) might be exploited in intracellular protein therapy.</p><sec id="sec5dot1-ijms-19-01781"><title>5.1. Intracellular functions&#x02014;Annexins as Biomarkers</title><p>Changes in cellular or tissue expression levels have been reported for several annexins and a broad range of diseases (<xref ref-type="fig" rid="ijms-19-01781-f001">Figure 1</xref>), suggesting a potential use to determine onset and progression of disease and to monitor therapeutic success. The following studies are exemplary only and illustrate the potential use of determining annexin expression profiles for the early detection of common cancers.</p><p>Massive dysregulation of annexin expression patterns occur during tumorigenesis. For instance, serum levels of AnxA1 are significantly elevated in lung cancer patients. Due to the strong association of AnxA1 to the pathological grade and clinical stage, it is a convenient marker for monitoring the course of disease [<xref rid="B100-ijms-19-01781" ref-type="bibr">100</xref>]. Furthermore, AnxA1 expression is upregulated in skeletal muscle of non-myopathic patients undergoing statin therapy, and was proposed to serve as a biomarker for T-tubular repair in those patients [<xref rid="B101-ijms-19-01781" ref-type="bibr">101</xref>].</p><p>Annexin expression profiles are often changed in tumorous tissues. For instance, the AnxA2 expression is significantly associated with tumor size, lymph node metastasis, distant metastasis and clinical stage of laryngeal cancer, and therefore it is a promising candidate for estimating the prognosis of patients with laryngeal carcinoma or gliomas [<xref rid="B102-ijms-19-01781" ref-type="bibr">102</xref>]. AnxA10 is already used as a biomarker for hepatocellular carcinoma (HCC) and is markedly downregulated during cancer progression [<xref rid="B103-ijms-19-01781" ref-type="bibr">103</xref>]. The AnxA10 downregulation, together with a characteristic p53 mutation, acts synergistically toward high-grade, high-stage HCC and goes along with poorer prognosis [<xref rid="B103-ijms-19-01781" ref-type="bibr">103</xref>]. AnxA10 might be useful to identify adenocarcinomas of unknown primary origin, as AnxA10 expression is commonly found in carcinoma of the upper gastrointestinal tract and the pancreatobiliary system [<xref rid="B104-ijms-19-01781" ref-type="bibr">104</xref>].</p></sec><sec id="sec5dot2-ijms-19-01781"><title>5.2. Intracellular Functions&#x02014;Regulation of Cytosolic Phospholipase A2 (cPLA2) Enzymatic Activity</title><p>Very early on, the ability of annexins, and especially AnxA1 and AnxA2, to inhibit cPLA2, thus interfering with arachidonic acid release and eicosanoid formation, has been acknowledged. Mechanistically, the function was explained by competition for the lipid substrates [<xref rid="B105-ijms-19-01781" ref-type="bibr">105</xref>,<xref rid="B106-ijms-19-01781" ref-type="bibr">106</xref>,<xref rid="B107-ijms-19-01781" ref-type="bibr">107</xref>]. However, cPLA2 might be inhibited in a more direct manner [<xref rid="B108-ijms-19-01781" ref-type="bibr">108</xref>]. Given the fundamental role of this enzymatic activity in eicosanoid production, annexins might serve as a starting point to discover new lead structures for further cPLA2 inhibitors.</p></sec><sec id="sec5dot3-ijms-19-01781"><title>5.3. Intracellular Functions&#x02014;Cell Surface Presentation of Integral Plasma Membrane Molecules</title><p>The AnxA2-S100A10 tetramer has been shown to interact with (and possibly regulate) a number of integral plasma membrane molecules including ion channels and receptors, like the Ca<sup>2+</sup>-selective Transient Receptor Potential vanilloid type 5 and 6 channels (TRPV5 and TRPV6) [<xref rid="B109-ijms-19-01781" ref-type="bibr">109</xref>], the acid-sensing ion channel ASIC [<xref rid="B110-ijms-19-01781" ref-type="bibr">110</xref>], the two-pore-domain potassium channel TASK-1 [<xref rid="B111-ijms-19-01781" ref-type="bibr">111</xref>], the chloride channel Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) [<xref rid="B112-ijms-19-01781" ref-type="bibr">112</xref>] the GPCR CCR10 [<xref rid="B113-ijms-19-01781" ref-type="bibr">113</xref>] and the 5-HT1B receptor [<xref rid="B114-ijms-19-01781" ref-type="bibr">114</xref>]. Interfering with these S100A10 interactions could be envisioned for the treatment of the corresponding diseases, including depression [<xref rid="B114-ijms-19-01781" ref-type="bibr">114</xref>], although a beneficial effect of an upregulation of S100A10 expression, e.g., through 1,25-dihydroxyvitamin D3 [<xref rid="B109-ijms-19-01781" ref-type="bibr">109</xref>], still needs to be demonstrated.</p><p>In many cases, altered annexin expression correlates with changes in migratory behaviour and invasiveness [<xref rid="B115-ijms-19-01781" ref-type="bibr">115</xref>,<xref rid="B116-ijms-19-01781" ref-type="bibr">116</xref>,<xref rid="B117-ijms-19-01781" ref-type="bibr">117</xref>,<xref rid="B118-ijms-19-01781" ref-type="bibr">118</xref>,<xref rid="B119-ijms-19-01781" ref-type="bibr">119</xref>,<xref rid="B120-ijms-19-01781" ref-type="bibr">120</xref>], and an altered cell surface environment might be the underlying cause. For instance, regulatory functions in the presentation of cell adhesion proteins, such as integrins, have been elegantly demonstrated for AnxA6 and AnxA8 [<xref rid="B115-ijms-19-01781" ref-type="bibr">115</xref>,<xref rid="B116-ijms-19-01781" ref-type="bibr">116</xref>]. Because these cell surface receptors cluster at focal contacts to form effective cell-cell or cell-matrix contacts, the number of integrins at the cell surface is a critical determinant of a cell&#x02019;s motility. Cell adhesion and movement, in turn, is fundamental to cancer cell metastasis, wound healing, and angiogenesis. In this context, the pattern of annexin gene expression may correlate to physiological and pathophysiological wound healing phenotypes. Such information would assist in assessing the course of healing within a wound, and in identifying target pathways for appropriate treatment regimes.</p></sec><sec id="sec5dot4-ijms-19-01781"><title>5.4. Intracellular Functions&#x02014;Plasma Membrane Repair</title><p>Very recently, another important annexin function related to cellular processes controlling damage appeared. To maintain a functional plasma membrane (PM), eukaryotic cells are able to repair PM injuries. The resealing is Ca<sup>2+</sup>-dependent and depends on a complex machinery. It can probably occur through different mechanisms, depending on the kind and extent of injury. PM repair is essential for skeletal muscle homeostasis, and defective PM repair manifests very impressively in skeletal muscle damage and is linked to degenerative muscle diseases such as myopathies and muscular dystrophies [<xref rid="B121-ijms-19-01781" ref-type="bibr">121</xref>]. A growing body of research suggests that several annexin family members facilitate the required membrane fusion events during the healing of PM lesions [<xref rid="B122-ijms-19-01781" ref-type="bibr">122</xref>,<xref rid="B123-ijms-19-01781" ref-type="bibr">123</xref>,<xref rid="B124-ijms-19-01781" ref-type="bibr">124</xref>,<xref rid="B125-ijms-19-01781" ref-type="bibr">125</xref>,<xref rid="B126-ijms-19-01781" ref-type="bibr">126</xref>,<xref rid="B127-ijms-19-01781" ref-type="bibr">127</xref>,<xref rid="B128-ijms-19-01781" ref-type="bibr">128</xref>]. Here, gene therapy, i.e., the transfer of DNA encoding functional annexin proteins into the target cells, might be used to treat conditions caused by defective PM repair mechanisms.</p></sec></sec><sec id="sec6-ijms-19-01781"><title>6. Annexins and the Host/Pathogen Interface</title><p>The growing appearance of antibiotic resistance is one of the major threats to human health. To overcome the emergence of drug-resistant viruses, bacteria, and fungi, therapeutic strategies that aim at targeting host cell factors rather than the pathogen itself are currently being pursued [<xref rid="B129-ijms-19-01781" ref-type="bibr">129</xref>]. However, most of these novel approaches are still in the very early phases of clinical trials. For the development of such novel approaches, detailed knowledge of the manifold host/pathogen interactions that take place during the course of infection, is paramount. An obvious target for interventions is the host innate immune response. It acts as a first line of defense against pathogen attack, and, not surprisingly, pathogens have evolved sophisticated strategies to overcome these cellular defense mechanisms or even use them to their advantage. Trypanosoma cruzi, for example, presents PS on the cell surface of trypomastigote stage in order to mimic the anti-inflammatory effects of apoptotic cells, thus evading the host innate immune response [<xref rid="B130-ijms-19-01781" ref-type="bibr">130</xref>]. A similar mechanism of apoptotic mimicry to balance inflammation is also used by <italic>Toxoplasma gondii</italic> [<xref rid="B131-ijms-19-01781" ref-type="bibr">131</xref>] and <italic>Leishmania braziliensis</italic> [<xref rid="B132-ijms-19-01781" ref-type="bibr">132</xref>], although it remains to be studied whether the immunomodulatory function also depends on the recruitment of AnxA1. However, blocking of the surface-exposed PS by AnxA5 impacts infectivity of <italic>Toxoplasma</italic> [<xref rid="B131-ijms-19-01781" ref-type="bibr">131</xref>] and <italic>Leishmania</italic> [<xref rid="B132-ijms-19-01781" ref-type="bibr">132</xref>]. These exemplary observations underscore that the elucidation of a functional role for the annexins during microbial infection, an emerging and rapidly growing field within the annexin research, holds potential for developing annexin-based therapeutic options.</p><p>Several annexins are incorporated into virus particles, for example, influenza A virus (IAV) particles contain annexins A1, A2, A4, A5, and A11 [<xref rid="B133-ijms-19-01781" ref-type="bibr">133</xref>]. In addition to IAV, AnxA1 is found associated with several other viruses [<xref rid="B133-ijms-19-01781" ref-type="bibr">133</xref>,<xref rid="B134-ijms-19-01781" ref-type="bibr">134</xref>,<xref rid="B135-ijms-19-01781" ref-type="bibr">135</xref>,<xref rid="B136-ijms-19-01781" ref-type="bibr">136</xref>,<xref rid="B137-ijms-19-01781" ref-type="bibr">137</xref>,<xref rid="B138-ijms-19-01781" ref-type="bibr">138</xref>,<xref rid="B139-ijms-19-01781" ref-type="bibr">139</xref>,<xref rid="B140-ijms-19-01781" ref-type="bibr">140</xref>,<xref rid="B141-ijms-19-01781" ref-type="bibr">141</xref>]. Interestingly, no indications so far suggest that the viruses rely on its immune-modulating capacity to facilitate virus entry, although the AnxA1 receptor FPR2 is involved in IAV replication. Notably, FPR2 activation increases viral replication, and FPR2 antagonists protect mice from lethal IAV infections [<xref rid="B142-ijms-19-01781" ref-type="bibr">142</xref>,<xref rid="B143-ijms-19-01781" ref-type="bibr">143</xref>]. A clearer active role during viral infection is found for AnxA2 and AnxA5. An exploitation of virus-incorporated AnxA2 to promote the conversion of plasminogen to plasmin on the cell surface was reported to be utilized, at least in a supportive manner, by herpesvirus and IAV [<xref rid="B144-ijms-19-01781" ref-type="bibr">144</xref>,<xref rid="B145-ijms-19-01781" ref-type="bibr">145</xref>,<xref rid="B146-ijms-19-01781" ref-type="bibr">146</xref>,<xref rid="B147-ijms-19-01781" ref-type="bibr">147</xref>]. Virus-incorporated AnxA5 assists IAV infection through the inhibition of interferon-mediated host cell protection [<xref rid="B148-ijms-19-01781" ref-type="bibr">148</xref>]. Whether the specific binding of anxA5 to a hepatitis B virus (HBV) surface antigen [<xref rid="B149-ijms-19-01781" ref-type="bibr">149</xref>,<xref rid="B150-ijms-19-01781" ref-type="bibr">150</xref>] mediates a similar function, thereby affecting the host cell susceptibility to HBV [<xref rid="B151-ijms-19-01781" ref-type="bibr">151</xref>,<xref rid="B152-ijms-19-01781" ref-type="bibr">152</xref>,<xref rid="B153-ijms-19-01781" ref-type="bibr">153</xref>,<xref rid="B154-ijms-19-01781" ref-type="bibr">154</xref>] remains to be investigated. Although the potential importance of the remaining IAV-associated annexins is still unknown, the above indications point to a function, at least for several annexins, as host-derived virulence factors. Furthermore, the most common high-risk human papillomavirus HPV16, which causes benign and malignant mucosal and cutaneous epithelial tumors, induces and utilizes the AnxA2/S100A10 heterotetramer on the host cell surface for effective internalization. The complex most likely interacts with the HPV minor capsid protein L2 [<xref rid="B155-ijms-19-01781" ref-type="bibr">155</xref>,<xref rid="B156-ijms-19-01781" ref-type="bibr">156</xref>]. Importantly, interfering with AnxA2/S100A10 complex through the use of small molecule inhibitors markedly impairs HPV16 infection in a cell culture model [<xref rid="B157-ijms-19-01781" ref-type="bibr">157</xref>]. Because a similar function for AnxA2 as a host cell receptor was also reported for several other viruses, including human cytomegalovirus, enterovirus type 71, rabbit vesivirus, and respiratory syncytial virus [<xref rid="B158-ijms-19-01781" ref-type="bibr">158</xref>,<xref rid="B159-ijms-19-01781" ref-type="bibr">159</xref>,<xref rid="B160-ijms-19-01781" ref-type="bibr">160</xref>,<xref rid="B161-ijms-19-01781" ref-type="bibr">161</xref>,<xref rid="B162-ijms-19-01781" ref-type="bibr">162</xref>,<xref rid="B163-ijms-19-01781" ref-type="bibr">163</xref>], as well as for <italic>Pseudomonas aeruginosa</italic> and <italic>Mycoplasma</italic> [<xref rid="B164-ijms-19-01781" ref-type="bibr">164</xref>,<xref rid="B165-ijms-19-01781" ref-type="bibr">165</xref>,<xref rid="B166-ijms-19-01781" ref-type="bibr">166</xref>], such small molecule inhibitors might be of therapeutic value in a broad range of viral and bacterial infections. Further host-directed drug therapies might include targeting of other annexin/pathogen interactions, for instance through the use of synthetic mimetic peptides that effectively compete for interaction sites.</p><p>Because of their biochemical signature, i.e., the ability to dynamically bind to membrane phospholipids (and for some annexins, to F-actin) in response to fluctuating intracellular Ca<sup>2+</sup> concentrations, annexins are perfectly suited to transduce and integrate membrane-related events and signaling. While there is a vast body of literature on their participation in e.g., endo- and exocytosis, membrane rearrangement events and cytoskeletal organization, growing evidence suggests that the establishment and control of membranes under non-equilibrium conditions is where the full annexin potential is unlocked. A predominant function of these proteins in the assembly of transient membrane domains and the maintenance of membrane integrity under potentially harmful conditions, such as PM disruption (see above) is also in accordance with the fact that annexin KO mice are viable, develop normally and have no evident phenotypic alterations during their lifetime [<xref rid="B23-ijms-19-01781" ref-type="bibr">23</xref>].</p><p>Because microbes in the human body intimately associate with the membrane system of their host cells, they have evolved sophisticated strategies to hijack the cell machinery and use it to their advantage [<xref rid="B167-ijms-19-01781" ref-type="bibr">167</xref>]. For instance, many invading pathogens need to penetrate the PM or endosomal membranes to get access to the cell interior in order to proliferate. These pathogen-induced membrane manipulations are potentially harmful, and a clear example is the insertion of pore-forming toxins, such as streptolysin-O (SLO), the pore-forming toxin of Streptococcus pyogenes. The host cell perceives the concomitant rise in intracellular Ca<sup>2+</sup> as a danger signal indicating PM injury, a situation that closely resembles PM damage induced by mechanical forces. In line with their proposed function as part of the repair machinery that kicks in when a high Ca<sup>2+</sup> influx is sensed [<xref rid="B20-ijms-19-01781" ref-type="bibr">20</xref>,<xref rid="B122-ijms-19-01781" ref-type="bibr">122</xref>], several annexins are involved in repairing the PM lesions caused by SLO [<xref rid="B168-ijms-19-01781" ref-type="bibr">168</xref>,<xref rid="B169-ijms-19-01781" ref-type="bibr">169</xref>]. This annexin-mediated resealing, blebbing, and subsequent shedding of the affected PM domains as pore-containing microvesicles is cell-protective and thus might constitute a vital part of the host cell innate immune response. The importance of the rapid and effective toxin removal for the host protection has been impressively demonstrated in vivo, as the administration of artificial liposomes that effectively compete with the host cell membranes sequester such toxins and successfully prevent the development of severe sepsis in a murine staphylococcal sepsis model [<xref rid="B170-ijms-19-01781" ref-type="bibr">170</xref>]. Another example of a pathogen exploiting the host cell PM repair mechanism is the induction of lysosomal exocytosis during the host cell entry process of adenoviruses [<xref rid="B171-ijms-19-01781" ref-type="bibr">171</xref>]. Fusion of lysosomes with the PM is also a means to control the propagation of intracellular bacteria [<xref rid="B172-ijms-19-01781" ref-type="bibr">172</xref>]. As annexins are involved in at least certain lysosomal fusion events [<xref rid="B173-ijms-19-01781" ref-type="bibr">173</xref>,<xref rid="B174-ijms-19-01781" ref-type="bibr">174</xref>], it is highly likely that they also play an important part in these pathogen-related events.</p><p>In many cases, annexin-mediated reorganization of intracellular membranes affects the pathogen propagation. IAV infection, for instance, is significantly reduced when AnxA6 is overexpressed, causing imbalanced cholesterol levels in the PM and endosomal membranes [<xref rid="B175-ijms-19-01781" ref-type="bibr">175</xref>]. AnxA2 and A3 are involved in the production of Hepatitis C virus (HCV) particles, presumably through supporting the establishment of the &#x0201c;membranous web&#x0201d;, the highly specialized and supposedly endoplasmatic reticulum (ER)-derived sites of HCV replication in infected cells [<xref rid="B176-ijms-19-01781" ref-type="bibr">176</xref>,<xref rid="B177-ijms-19-01781" ref-type="bibr">177</xref>,<xref rid="B178-ijms-19-01781" ref-type="bibr">178</xref>] and affecting HCV maturation and egress [<xref rid="B179-ijms-19-01781" ref-type="bibr">179</xref>].</p><p>These examples are certainly far from being complete, but were selected to highlight the potential therapeutic value of the annexins in the development of novel, host-centered approaches, either as lead substances for drug design or promising targets in pathogen&#x02013;host cell interactions.</p></sec><sec id="sec7-ijms-19-01781"><title>7. Conclusions</title><p>This review summarizes the potential clinical use of the annexins. While by no means exhaustive (we apologize to any colleague whose excellent work had to be excluded in the interest of space), we believe that the special issue &#x0201c;Annexins&#x02014;Closing the Gap between Fundamental and Translational Research&#x0201d; is a collection of exemplary articles that helps bring together annexin-themed basic science and translational research which will inspire a fresh look and open up a whole new world where these proteins can be conquered.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Volker Gerke for his critical and careful reading of the manuscript and his helpful suggestions.</p></ack><notes><title>Author Contributions</title><p>All authors have made substantial contributions to the manuscript. Conceptualization, S.S. and U.R. Data Curation, S.S. and D.P.; Writing&#x02014;Original Draft Preparation, S.S.; D.P. Writing&#x02014;Review &#x00026; Editing, S.S.; D.P.; U.R. Supervision, U.R.; Project Administration, U.R.; Funding Acquisition, U.R.</p></notes><notes><title>Funding</title><p>This work was supported by funding to U.R. from the Interdisciplinary Center of Clinical Research of the M&#x000fc;nster Medical School (IZKF, RE2/026/15) and the German Research Foundation (DFG; SFB1009/A06 and SFB 1348/A11). Authors are members of the phi Club of the M&#x000fc;nster Alliance for Infection Research.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-ijms-19-01781"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creutz</surname><given-names>C.E.</given-names></name><name><surname>Pazoles</surname><given-names>C.J.</given-names></name><name><surname>Pollard</surname><given-names>H.B.</given-names></name></person-group><article-title>Identification and purification of an adrenal medullary protein (synexin) that causes calcium-dependent aggregation of isolated chromaffin granules</article-title><source>J. Biol. Chem.</source><year>1978</year><volume>253</volume><fpage>2858</fpage><lpage>2866</lpage><?supplied-pmid 632306?><pub-id pub-id-type="pmid">632306</pub-id></element-citation></ref><ref id="B2-ijms-19-01781"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geisow</surname><given-names>M.J.</given-names></name><name><surname>Walker</surname><given-names>J.H.</given-names></name><name><surname>Boustead</surname><given-names>C.</given-names></name><name><surname>Taylor</surname><given-names>W.</given-names></name></person-group><article-title>Annexins&#x02014;New family of Ca<sup>2+</sup>-regulated-phospholipid binding protein</article-title><source>Biosci. Rep.</source><year>1987</year><volume>7</volume><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1007/BF01121450</pub-id><?supplied-pmid 2960386?><pub-id pub-id-type="pmid">2960386</pub-id></element-citation></ref><ref id="B3-ijms-19-01781"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>R.</given-names></name><name><surname>Fernandez</surname><given-names>M.P.</given-names></name></person-group><article-title>Structure, Function and Evolution of the Annexin Gene Superfamily</article-title><source>Annexins: Biological Importance and Annexin-Related Pathologies</source><person-group person-group-type="editor"><name><surname>Bandorowicz-Pikula</surname><given-names>J.</given-names></name></person-group><publisher-name>Kluwer Academic/Plenum Publishers</publisher-name><publisher-loc>Georgetown, WA, USA</publisher-loc><year>2003</year><fpage>21</fpage><lpage>37</lpage></element-citation></ref><ref id="B4-ijms-19-01781"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname><given-names>R.O.</given-names></name><name><surname>Bell</surname><given-names>D.W.</given-names></name><name><surname>Testa</surname><given-names>J.R.</given-names></name><name><surname>Fernandez</surname><given-names>M.P.</given-names></name></person-group><article-title>Human annexin 31 genetic mapping and origin</article-title><source>Gene</source><year>1999</year><volume>227</volume><fpage>33</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/S0378-1119(98)00597-6</pub-id><pub-id pub-id-type="pmid">9931420</pub-id></element-citation></ref><ref id="B5-ijms-19-01781"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>G.J.</given-names></name><name><surname>Newman</surname><given-names>R.H.</given-names></name><name><surname>Freemont</surname><given-names>P.S.</given-names></name><name><surname>Crumpton</surname><given-names>M.J.</given-names></name></person-group><article-title>Amino acid sequence analysis of the annexin super-gene family of proteins</article-title><source>Eur. J. Biochem.</source><year>1991</year><volume>198</volume><fpage>749</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1991.tb16076.x</pub-id><?supplied-pmid 1646719?><pub-id pub-id-type="pmid">1646719</pub-id></element-citation></ref><ref id="B6-ijms-19-01781"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group><article-title>S100A10/p11: Family, friends and functions</article-title><source>Pfl&#x000fc;gers Arch. Eur. J. Physiol.</source><year>2007</year><volume>455</volume><fpage>575</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1007/s00424-007-0313-4</pub-id><?supplied-pmid 17638009?><pub-id pub-id-type="pmid">17638009</pub-id></element-citation></ref><ref id="B7-ijms-19-01781"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kheifets</surname><given-names>V.</given-names></name><name><surname>Bright</surname><given-names>R.</given-names></name><name><surname>Inagaki</surname><given-names>K.</given-names></name><name><surname>Schechtman</surname><given-names>D.</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D.</given-names></name></person-group><article-title>Protein kinase C &#x003b4; (&#x003b4;PKC)-annexin V interaction: A required step in &#x003b4;PKC translocation and function</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>23218</fpage><lpage>23226</lpage><pub-id pub-id-type="doi">10.1074/jbc.M602075200</pub-id><?supplied-pmid 16785226?><pub-id pub-id-type="pmid">16785226</pub-id></element-citation></ref><ref id="B8-ijms-19-01781"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erikson</surname><given-names>E.</given-names></name><name><surname>Erikson</surname><given-names>R.L.</given-names></name></person-group><article-title>Identification of a Cellular Protein Substrate Phosphorylated by the Avian Sarcoma Virus- Transforming Gene Product</article-title><source>Cell. Copyr.</source><year>1980</year><volume>21</volume><fpage>829</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(80)90446-8</pub-id></element-citation></ref><ref id="B9-ijms-19-01781"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>M.J.</given-names></name><name><surname>Moss</surname><given-names>S.E.</given-names></name></person-group><article-title>Annexin 2 has a dual role as regulator and effector of v-Src in cell transformation</article-title><source>J. Biol. Chem.</source><year>2009</year><volume>284</volume><fpage>10202</fpage><lpage>10210</lpage><pub-id pub-id-type="doi">10.1074/jbc.M807043200</pub-id><?supplied-pmid 19193640?><pub-id pub-id-type="pmid">19193640</pub-id></element-citation></ref><ref id="B10-ijms-19-01781"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Moss</surname><given-names>S.E.</given-names></name></person-group><article-title>Annexins: From Structure to Function</article-title><source>Physiol. Rev.</source><year>2002</year><volume>82</volume><fpage>331</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1152/physrev.00030.2001</pub-id><?supplied-pmid 11917092?><pub-id pub-id-type="pmid">11917092</pub-id></element-citation></ref><ref id="B11-ijms-19-01781"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croxtall</surname><given-names>J.D.</given-names></name><name><surname>Choudhury</surname><given-names>Q.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name></person-group><article-title>Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism</article-title><source>Br. J. Pharmacol.</source><year>2000</year><volume>130</volume><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0703272</pub-id><?supplied-pmid 10807665?><pub-id pub-id-type="pmid">10807665</pub-id></element-citation></ref><ref id="B12-ijms-19-01781"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>C.D.</given-names></name><name><surname>Christian</surname><given-names>H.C.</given-names></name><name><surname>Morris</surname><given-names>J.F.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Solito</surname><given-names>E.</given-names></name><name><surname>Buckingham</surname><given-names>J.C.</given-names></name></person-group><article-title>Kinase-dependent regulation of the secretion of thyrotrophin and luteinizing hormone by glucocorticoids and annexin 1 peptides</article-title><source>J. Neuroendocrinol.</source><year>2003</year><volume>15</volume><fpage>946</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2826.2003.01081.x</pub-id><?supplied-pmid 12969239?><pub-id pub-id-type="pmid">12969239</pub-id></element-citation></ref><ref id="B13-ijms-19-01781"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Acquisto</surname><given-names>F.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name></person-group><article-title>Annexin-A1: A pivotal regulator of the innate and adaptive immune systems</article-title><source>Br. J. Pharmacol.</source><year>2008</year><volume>155</volume><fpage>152</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.252</pub-id><?supplied-pmid 18641677?><pub-id pub-id-type="pmid">18641677</pub-id></element-citation></ref><ref id="B14-ijms-19-01781"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solito</surname><given-names>E.</given-names></name><name><surname>Christian</surname><given-names>H.C.</given-names></name><name><surname>Festa</surname><given-names>M.</given-names></name><name><surname>Mulla</surname><given-names>A.</given-names></name><name><surname>Tierney</surname><given-names>T.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Buckingham</surname><given-names>J.C.</given-names></name></person-group><article-title>Post-translational modification plays an essential role in the translocation of annexin A1 from the cytoplasm to the cell surface</article-title><source>FASEB J.</source><year>2006</year><volume>20</volume><fpage>1498</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.1096/fj.05-5319fje</pub-id><?supplied-pmid 16720734?><pub-id pub-id-type="pmid">16720734</pub-id></element-citation></ref><ref id="B15-ijms-19-01781"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>K.</given-names></name><name><surname>Sui</surname><given-names>G.</given-names></name><name><surname>Xiong</surname><given-names>H.</given-names></name><name><surname>Broekman</surname><given-names>M.J.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Marcus</surname><given-names>A.J.</given-names></name><name><surname>Hajjar</surname><given-names>K.A.</given-names></name></person-group><article-title>Feedback regulation of endothelial cell surface plasmin generation by PKC-dependent phosphorylation of annexin A2</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>15428</fpage><lpage>15439</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.185058</pub-id><?supplied-pmid 21115493?><pub-id pub-id-type="pmid">21115493</pub-id></element-citation></ref><ref id="B16-ijms-19-01781"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>Annexins&#x02014;Unique membrane binding proteins with diverse functions</article-title><source>J. Cell Sci.</source><year>2004</year><volume>117</volume><fpage>2631</fpage><lpage>2639</lpage><pub-id pub-id-type="doi">10.1242/jcs.01245</pub-id><?supplied-pmid 15169834?><pub-id pub-id-type="pmid">15169834</pub-id></element-citation></ref><ref id="B17-ijms-19-01781"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>M.J.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Moss</surname><given-names>S.E.</given-names></name></person-group><article-title>Annexin-Actin interactions</article-title><source>Traffic</source><year>2004</year><volume>5</volume><fpage>571</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0854.2004.00210.x</pub-id><?supplied-pmid 15260827?><pub-id pub-id-type="pmid">15260827</pub-id></element-citation></ref><ref id="B18-ijms-19-01781"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creutz</surname><given-names>C.E.</given-names></name></person-group><article-title>The annexins and exocytosis</article-title><source>Science</source><year>1992</year><volume>258</volume><fpage>924</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1126/science.1439804</pub-id><?supplied-pmid 1439804?><pub-id pub-id-type="pmid">1439804</pub-id></element-citation></ref><ref id="B19-ijms-19-01781"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meers</surname><given-names>P.</given-names></name><name><surname>Mealy</surname><given-names>T.</given-names></name><name><surname>Pavlotsky</surname><given-names>N.</given-names></name><name><surname>Tauber</surname><given-names>A.I.</given-names></name></person-group><article-title>Annexin I-Mediated Vesicular Aggregation: Mechanism and Role in Human Neutrophils</article-title><source>Biochemistry</source><year>1992</year><volume>31</volume><fpage>6372</fpage><lpage>6382</lpage><pub-id pub-id-type="doi">10.1021/bi00143a003</pub-id><?supplied-pmid 1385975?><pub-id pub-id-type="pmid">1385975</pub-id></element-citation></ref><ref id="B20-ijms-19-01781"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draeger</surname><given-names>A.</given-names></name><name><surname>Wray</surname><given-names>S.</given-names></name><name><surname>Babiychuk</surname><given-names>E.B.</given-names></name></person-group><article-title>Domain architecture of the smooth-muscle plasma membrane: Regulation by annexins</article-title><source>Biochem. J.</source><year>2005</year><volume>387</volume><fpage>309</fpage><lpage>314</lpage><pub-id pub-id-type="doi">10.1042/BJ20041363</pub-id><?supplied-pmid 15537390?><pub-id pub-id-type="pmid">15537390</pub-id></element-citation></ref><ref id="B21-ijms-19-01781"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeil</surname><given-names>A.K.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>McNeil</surname><given-names>P.L.</given-names></name></person-group><article-title>Requirement for annexin A1 in plasma membrane repair</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>35202</fpage><lpage>35207</lpage><pub-id pub-id-type="doi">10.1074/jbc.M606406200</pub-id><?supplied-pmid 16984915?><pub-id pub-id-type="pmid">16984915</pub-id></element-citation></ref><ref id="B22-ijms-19-01781"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuehnl</surname><given-names>A.</given-names></name><name><surname>Musiol</surname><given-names>A.</given-names></name><name><surname>Raabe</surname><given-names>C.A.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>Emerging functions as host cell factors&#x02014;An encyclopedia of annexin-pathogen interactions</article-title><source>Biol. Chem.</source><year>2016</year><volume>397</volume><fpage>949</fpage><lpage>959</lpage><pub-id pub-id-type="doi">10.1515/hsz-2016-0183</pub-id><?supplied-pmid 27366904?><pub-id pub-id-type="pmid">27366904</pub-id></element-citation></ref><ref id="B23-ijms-19-01781"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grewal</surname><given-names>T.</given-names></name><name><surname>Wason</surname><given-names>S.J.</given-names></name><name><surname>Enrich</surname><given-names>C.</given-names></name><name><surname>Rentero</surname><given-names>C.</given-names></name></person-group><article-title>Annexins&#x02013;insights from knockout mice</article-title><source>Biol. Chem.</source><year>2016</year><volume>397</volume><fpage>1031</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1515/hsz-2016-0168</pub-id><?supplied-pmid 27318360?><pub-id pub-id-type="pmid">27318360</pub-id></element-citation></ref><ref id="B24-ijms-19-01781"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenis</surname><given-names>H.</given-names></name><name><surname>van Genderen</surname><given-names>H.</given-names></name><name><surname>Bennaghmouch</surname><given-names>A.</given-names></name><name><surname>Rinia</surname><given-names>H.A.</given-names></name><name><surname>Frederik</surname><given-names>P.</given-names></name><name><surname>Narula</surname><given-names>J.</given-names></name><name><surname>Hofstra</surname><given-names>L.</given-names></name><name><surname>Reutelingsperger</surname><given-names>C.P.M.</given-names></name></person-group><article-title>Cell surface-expressed phosphatidylserine and annexin A5 open a novel portal of cell entry</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>52623</fpage><lpage>52629</lpage><pub-id pub-id-type="doi">10.1074/jbc.M409009200</pub-id><?supplied-pmid 15381697?><pub-id pub-id-type="pmid">15381697</pub-id></element-citation></ref><ref id="B25-ijms-19-01781"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenis</surname><given-names>H.</given-names></name><name><surname>Hofstra</surname><given-names>L.</given-names></name><name><surname>Reutelingsperger</surname><given-names>C.P.M.</given-names></name></person-group><article-title>Annexin A5: Shifting from a diagnostic towards a therapeutic realm</article-title><source>Cell. Mol. Life Sci.</source><year>2007</year><volume>64</volume><fpage>2859</fpage><lpage>2862</lpage><pub-id pub-id-type="doi">10.1007/s00018-007-7297-2</pub-id><?supplied-pmid 17876516?><pub-id pub-id-type="pmid">17876516</pub-id></element-citation></ref><ref id="B26-ijms-19-01781"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andree</surname><given-names>H.A.</given-names></name><name><surname>Reutelingsperger</surname><given-names>C.P.</given-names></name><name><surname>Hauptmann</surname><given-names>R.</given-names></name><name><surname>Hemker</surname><given-names>H.C.</given-names></name><name><surname>Hermens</surname><given-names>W.T.</given-names></name><name><surname>Willems</surname><given-names>G.M.</given-names></name></person-group><article-title>Binding of vascular anticoagulant &#x003b1; (VAC &#x003b1;) to planar phospholipid bilayers</article-title><source>J. Biol. Chem.</source><year>1990</year><volume>265</volume><fpage>4923</fpage><lpage>4928</lpage><?supplied-pmid 2138622?><pub-id pub-id-type="pmid">2138622</pub-id></element-citation></ref><ref id="B27-ijms-19-01781"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fadok</surname><given-names>V.A.</given-names></name><name><surname>Voelker</surname><given-names>D.R.</given-names></name><name><surname>Campbell</surname><given-names>P.A.</given-names></name><name><surname>Cohen</surname><given-names>J.J.</given-names></name><name><surname>Bratton</surname><given-names>D.L.</given-names></name><name><surname>Henson</surname><given-names>P.M.</given-names></name></person-group><article-title>Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages</article-title><source>J. Immunol.</source><year>1992</year><volume>148</volume><fpage>2207</fpage><lpage>2216</lpage><?supplied-pmid 1545126?><pub-id pub-id-type="pmid">1545126</pub-id></element-citation></ref><ref id="B28-ijms-19-01781"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Engeland</surname><given-names>M.</given-names></name><name><surname>Kuijpers</surname><given-names>H.J.H.</given-names></name><name><surname>Ramaekers</surname><given-names>F.C.S.</given-names></name><name><surname>Reutelingsperger</surname><given-names>C.P.M.</given-names></name><name><surname>Schutte</surname><given-names>B.</given-names></name></person-group><article-title>Plasma Membrane Alterations and Cytoskeletal Changes in Apoptosis</article-title><source>Exp. Cell Res.</source><year>1997</year><volume>235</volume><fpage>421</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1006/excr.1997.3738</pub-id><?supplied-pmid 9299167?><pub-id pub-id-type="pmid">9299167</pub-id></element-citation></ref><ref id="B29-ijms-19-01781"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boersma</surname><given-names>H.H.</given-names></name><name><surname>Kietselaer</surname><given-names>B.L.J.H.</given-names></name><name><surname>Stolk</surname><given-names>L.M.L.</given-names></name><name><surname>Bennaghmouch</surname><given-names>A.</given-names></name><name><surname>Hofstra</surname><given-names>L.</given-names></name><name><surname>Narula</surname><given-names>J.</given-names></name><name><surname>Heidendal</surname><given-names>G.A.K.</given-names></name><name><surname>Reutelingsperger</surname><given-names>C.P.M.</given-names></name></person-group><article-title>Past, present, and future of annexin A5: From protein discovery to clinical applications</article-title><source>J. Nucl. Med.</source><year>2005</year><volume>46</volume><fpage>2035</fpage><lpage>2050</lpage><?supplied-pmid 16330568?><pub-id pub-id-type="pmid">16330568</pub-id></element-citation></ref><ref id="B30-ijms-19-01781"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>S.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name></person-group><article-title>Programmed cell death and the immune system</article-title><source>Nat. Rev. Immunol.</source><year>2017</year><volume>17</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.153</pub-id><?supplied-pmid 28163302?><pub-id pub-id-type="pmid">28163302</pub-id></element-citation></ref><ref id="B31-ijms-19-01781"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arur</surname><given-names>S.</given-names></name><name><surname>Uche</surname><given-names>U.E.</given-names></name><name><surname>Rezaul</surname><given-names>K.</given-names></name><name><surname>Fong</surname><given-names>M.</given-names></name><name><surname>Scranton</surname><given-names>V.</given-names></name><name><surname>Cowan</surname><given-names>A.E.</given-names></name><name><surname>Mohler</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>D.K.</given-names></name></person-group><article-title>Annexin I is an endogenous ligand that mediates apoptotic cell engulfment</article-title><source>Dev. Cell.</source><year>2003</year><volume>4</volume><fpage>587</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(03)00090-X</pub-id><pub-id pub-id-type="pmid">12689596</pub-id></element-citation></ref><ref id="B32-ijms-19-01781"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pupjalis</surname><given-names>D.</given-names></name><name><surname>Goetsch</surname><given-names>J.</given-names></name><name><surname>Kottas</surname><given-names>D.J.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signalling</article-title><source>EMBO Mol. Med.</source><year>2011</year><volume>3</volume><fpage>102</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1002/emmm.201000113</pub-id><?supplied-pmid 21254404?><pub-id pub-id-type="pmid">21254404</pub-id></element-citation></ref><ref id="B33-ijms-19-01781"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asano</surname><given-names>K.</given-names></name><name><surname>Miwa</surname><given-names>M.</given-names></name><name><surname>Miwa</surname><given-names>K.</given-names></name><name><surname>Hanayama</surname><given-names>R.</given-names></name><name><surname>Nagase</surname><given-names>H.</given-names></name><name><surname>Nagata</surname><given-names>S.</given-names></name><name><surname>Tanaka</surname><given-names>M.</given-names></name></person-group><article-title>Masking of phosphatidylserine inhibits apoptotic cell engulfment and induces autoantibody production in mice</article-title><source>J. Exp. Med.</source><year>2004</year><volume>200</volume><fpage>459</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1084/jem.20040342</pub-id><?supplied-pmid 15302904?><pub-id pub-id-type="pmid">15302904</pub-id></element-citation></ref><ref id="B34-ijms-19-01781"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birge</surname><given-names>R.B.</given-names></name><name><surname>Boeltz</surname><given-names>S.</given-names></name><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Carlson</surname><given-names>J.</given-names></name><name><surname>Wanderley</surname><given-names>J.</given-names></name><name><surname>Calianese</surname><given-names>D.</given-names></name><name><surname>Barcinski</surname><given-names>M.</given-names></name><name><surname>Brekken</surname><given-names>R.A.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Hutchins</surname><given-names>J.T.</given-names></name><etal/></person-group><article-title>Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer</article-title><source>Cell Death Differ.</source><year>2016</year><volume>23</volume><fpage>962</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.11</pub-id><?supplied-pmid 26915293?><pub-id pub-id-type="pmid">26915293</pub-id></element-citation></ref><ref id="B35-ijms-19-01781"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>B.</given-names></name><name><surname>Kanwar</surname><given-names>S.S.</given-names></name></person-group><article-title>Phosphatidylserine: A cancer cell targeting biomarker</article-title><source>Semin. Cancer Biol.</source><year>2017</year><pub-id pub-id-type="doi">10.1016/j.semcancer.2017.08.012</pub-id><?supplied-pmid 28870843?><pub-id pub-id-type="pmid">28870843</pub-id></element-citation></ref><ref id="B36-ijms-19-01781"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Durr</surname><given-names>E.</given-names></name><name><surname>Krasinska</surname><given-names>K.M.</given-names></name><name><surname>Carver</surname><given-names>L.A.</given-names></name><name><surname>Testa</surname><given-names>J.E.</given-names></name><name><surname>Schnitzer</surname><given-names>J.E.</given-names></name></person-group><article-title>Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy</article-title><source>Nature</source><year>2004</year><volume>429</volume><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1038/nature02580</pub-id><?supplied-pmid 15190345?><pub-id pub-id-type="pmid">15190345</pub-id></element-citation></ref><ref id="B37-ijms-19-01781"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>B.</given-names></name><name><surname>Guo</surname><given-names>C.</given-names></name><name><surname>Guan</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>M.-Z.</given-names></name></person-group><article-title>Annexin A5 as a potential marker in tumors</article-title><source>Clin. Chim. Acta</source><year>2014</year><volume>427</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2013.09.048</pub-id><?supplied-pmid 24121031?><pub-id pub-id-type="pmid">24121031</pub-id></element-citation></ref><ref id="B38-ijms-19-01781"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>L.G.</given-names></name><name><surname>Monteiro</surname><given-names>R.Q.</given-names></name></person-group><article-title>Activation of blood coagulation in cancer: Implications for tumour progression</article-title><source>Biosci. Rep.</source><year>2013</year><volume>33</volume><pub-id pub-id-type="doi">10.1042/BSR20130057</pub-id><?supplied-pmid 23889169?><pub-id pub-id-type="pmid">23889169</pub-id></element-citation></ref><ref id="B39-ijms-19-01781"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lentz</surname><given-names>B.R.</given-names></name></person-group><article-title>Exposure of platelet membrane phosphatidylserine regulates blood coagulation</article-title><source>Prog. Lipid Res.</source><year>2003</year><volume>42</volume><fpage>423</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1016/S0163-7827(03)00025-0</pub-id><pub-id pub-id-type="pmid">12814644</pub-id></element-citation></ref><ref id="B40-ijms-19-01781"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ormesher</surname><given-names>L.</given-names></name><name><surname>Greer</surname><given-names>I.A.</given-names></name></person-group><article-title>ANXA5: A key to unlock the mystery of the spectrum of placental-mediated pregnancy complications?</article-title><source>Womens Health</source><year>2016</year><volume>12</volume><fpage>159</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.2217/whe-2015-0003</pub-id><?supplied-pmid 26901843?><pub-id pub-id-type="pmid">26901843</pub-id></element-citation></ref><ref id="B41-ijms-19-01781"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogdanova</surname><given-names>N.</given-names></name><name><surname>Horst</surname><given-names>J.</given-names></name><name><surname>Chlystun</surname><given-names>M.</given-names></name><name><surname>Croucher</surname><given-names>P.J.P.</given-names></name><name><surname>Nebel</surname><given-names>A.</given-names></name><name><surname>Bohring</surname><given-names>A.</given-names></name><name><surname>Todorova</surname><given-names>A.</given-names></name><name><surname>Schreiber</surname><given-names>S.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Krawczak</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A common haplotype of the annexin A5 (<italic>ANXA5</italic>) gene promoter is associated with recurrent pregnancy loss</article-title><source>Hum. Mol. Genet.</source><year>2007</year><volume>16</volume><fpage>573</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddm017</pub-id><?supplied-pmid 17339269?><pub-id pub-id-type="pmid">17339269</pub-id></element-citation></ref><ref id="B42-ijms-19-01781"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oling</surname><given-names>F.</given-names></name><name><surname>Sopkova-De</surname><given-names>J.</given-names></name><name><surname>Santos</surname><given-names>O.</given-names></name><name><surname>Govorukhina</surname><given-names>N.</given-names></name><name><surname>Maze</surname><given-names>C.</given-names></name><name><surname>Res-Dubut</surname><given-names>&#x000c1;.</given-names></name><name><surname>Bergsma-Schutter</surname><given-names>W.</given-names></name><name><surname>Oostergetel</surname><given-names>G.</given-names></name><name><surname>Keegstra</surname><given-names>W.</given-names></name><name><surname>Lambert</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Structure of Membrane-bound Annexin A5 Trimers: A Hybrid Cryo-EM-X-ray Crystallography Study</article-title><source>J. Mol. Biol.</source><year>2000</year><volume>4</volume><fpage>561</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1006/jmbi.2000.4183</pub-id><?supplied-pmid 11099380?><pub-id pub-id-type="pmid">11099380</pub-id></element-citation></ref><ref id="B43-ijms-19-01781"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>J.H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Lapinski</surname><given-names>R.</given-names></name><name><surname>van Heerde</surname><given-names>W.L.</given-names></name><name><surname>Reutelingsperger</surname><given-names>C.P.</given-names></name><name><surname>Chen</surname><given-names>P.P.</given-names></name><name><surname>Ortel</surname><given-names>T.L.</given-names></name></person-group><article-title>Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome</article-title><source>Blood</source><year>2004</year><volume>104</volume><fpage>2783</fpage><lpage>2790</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-01-0203</pub-id><?supplied-pmid 15242878?><pub-id pub-id-type="pmid">15242878</pub-id></element-citation></ref><ref id="B44-ijms-19-01781"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negrini</surname><given-names>S.</given-names></name><name><surname>Pappalardo</surname><given-names>F.</given-names></name><name><surname>Murdaca</surname><given-names>G.</given-names></name><name><surname>Indiveri</surname><given-names>F.</given-names></name><name><surname>Puppo</surname><given-names>F.</given-names></name></person-group><article-title>The antiphospholipid syndrome: From pathophysiology to treatment</article-title><source>Clin. Exp. Med.</source><year>2017</year><volume>17</volume><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1007/s10238-016-0430-5</pub-id><?supplied-pmid 27334977?><pub-id pub-id-type="pmid">27334977</pub-id></element-citation></ref><ref id="B45-ijms-19-01781"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Garc&#x000ed;a</surname><given-names>M.I.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>J.A.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>A.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>M.P.</given-names></name><name><surname>Gutierrez</surname><given-names>C.</given-names></name><name><surname>Torre-Alonso</surname><given-names>J.C.</given-names></name></person-group><article-title>Annexin V autoantibodies in rheumatoid arthritis</article-title><source>Ann. Rheum. Dis.</source><year>1996</year><volume>55</volume><fpage>895</fpage><lpage>900</lpage><pub-id pub-id-type="doi">10.1136/ard.55.12.895</pub-id><?supplied-pmid 9014583?><pub-id pub-id-type="pmid">9014583</pub-id></element-citation></ref><ref id="B46-ijms-19-01781"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scholz</surname><given-names>P.</given-names></name><name><surname>Auler</surname><given-names>M.</given-names></name><name><surname>Brachvogel</surname><given-names>B.</given-names></name><name><surname>Benzing</surname><given-names>T.</given-names></name><name><surname>Mallman</surname><given-names>P.</given-names></name><name><surname>Streichert</surname><given-names>T.</given-names></name><name><surname>Klatt</surname><given-names>A.R.</given-names></name></person-group><article-title>Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome</article-title><source>Biochem. Med.</source><year>2016</year><volume>26</volume><fpage>272</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.11613/BM.2016.032</pub-id><?supplied-pmid 27346975?><pub-id pub-id-type="pmid">27346975</pub-id></element-citation></ref><ref id="B47-ijms-19-01781"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>M.</given-names></name><name><surname>MacLeod</surname><given-names>T.J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Waisman</surname><given-names>D.</given-names></name></person-group><article-title>S100A10, annexin A2, and annexin A2 heterotetramer as candidate plasminogen receptors</article-title><source>Front. Biosci.</source><year>2005</year><volume>10</volume><fpage>300</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.2741/1529</pub-id><?supplied-pmid 15574370?><pub-id pub-id-type="pmid">15574370</pub-id></element-citation></ref><ref id="B48-ijms-19-01781"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajjar</surname><given-names>K.A.</given-names></name></person-group><article-title>The Biology of Annexin A2: From Vascular Fibrinolysis to Innate Immunity</article-title><source>Trans. Am. Clin. Climatol. Assoc.</source><year>2015</year><volume>126</volume><fpage>144</fpage><lpage>155</lpage><?supplied-pmid 26330668?><pub-id pub-id-type="pmid">26330668</pub-id></element-citation></ref><ref id="B49-ijms-19-01781"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>Q.</given-names></name><name><surname>Jacovina</surname><given-names>A.T.</given-names></name><name><surname>Deora</surname><given-names>A.</given-names></name><name><surname>Febbraio</surname><given-names>M.</given-names></name><name><surname>Simantov</surname><given-names>R.</given-names></name><name><surname>Silverstein</surname><given-names>R.L.</given-names></name><name><surname>Hempstead</surname><given-names>B.</given-names></name><name><surname>Mark</surname><given-names>W.H.</given-names></name><name><surname>Hajjar</surname><given-names>K.A.</given-names></name></person-group><article-title>Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo</article-title><source>J. Clin. Invest.</source><year>2004</year><volume>113</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1172/JCI19684</pub-id><?supplied-pmid 14702107?><pub-id pub-id-type="pmid">14702107</pub-id></element-citation></ref><ref id="B50-ijms-19-01781"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menell</surname><given-names>J.S.</given-names></name><name><surname>Cesarman</surname><given-names>G.M.</given-names></name><name><surname>Jacovina</surname><given-names>A.T.</given-names></name><name><surname>McLaughlin</surname><given-names>M.A.</given-names></name><name><surname>Lev</surname><given-names>E.A.</given-names></name><name><surname>Hajjar</surname><given-names>K.A.</given-names></name></person-group><article-title>Annexin II and Bleeding in Acute Promyelocytic Leukemia</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>340</volume><fpage>994</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1056/NEJM199904013401303</pub-id><?supplied-pmid 10099141?><pub-id pub-id-type="pmid">10099141</pub-id></element-citation></ref><ref id="B51-ijms-19-01781"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannon</surname><given-names>R.</given-names></name><name><surname>Croxtall</surname><given-names>J.D.</given-names></name><name><surname>Getting</surname><given-names>S.J.</given-names></name><name><surname>Roviezzo</surname><given-names>F.</given-names></name><name><surname>Yona</surname><given-names>S.</given-names></name><name><surname>Paul-Clark</surname><given-names>M.J.</given-names></name><name><surname>Gavins</surname><given-names>F.N.E.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Morris</surname><given-names>J.F.</given-names></name><name><surname>Buckingham</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Aberrant inflammation and resistance to glucocorticoids in <italic>Annexin 1</italic><sup>&#x02212;/&#x02212;</sup> Mouse</article-title><source>FASEB J.</source><year>2002</year><volume>17</volume><fpage>253</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1096/fj.02-0239fje</pub-id><?supplied-pmid 12475898?><pub-id pub-id-type="pmid">12475898</pub-id></element-citation></ref><ref id="B52-ijms-19-01781"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vong</surname><given-names>L.</given-names></name><name><surname>D&#x02019;Acquisto</surname><given-names>F.</given-names></name><name><surname>Pederzoli-Ribeil</surname><given-names>M.</given-names></name><name><surname>Lavagno</surname><given-names>L.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Witko-Sarsat</surname><given-names>V.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group><article-title>Annexin 1 cleavage in activated neutrophils: A pivotal role for proteinase 3</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>29998</fpage><lpage>30004</lpage><pub-id pub-id-type="doi">10.1074/jbc.M702876200</pub-id><?supplied-pmid 17681950?><pub-id pub-id-type="pmid">17681950</pub-id></element-citation></ref><ref id="B53-ijms-19-01781"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name></person-group><article-title>Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics</article-title><source>Br. J. Pharmacol.</source><year>2009</year><volume>158</volume><fpage>936</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00483.x</pub-id><?supplied-pmid 19845684?><pub-id pub-id-type="pmid">19845684</pub-id></element-citation></ref><ref id="B54-ijms-19-01781"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>D&#x02019;Acquisto</surname><given-names>F.</given-names></name></person-group><article-title>Annexin A1 and glucocorticoids as effectors of the resolution of inflammation</article-title><source>Nat. Rev. Immunol.</source><year>2009</year><volume>9</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nri2470</pub-id><?supplied-pmid 19104500?><pub-id pub-id-type="pmid">19104500</pub-id></element-citation></ref><ref id="B55-ijms-19-01781"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamal</surname><given-names>A.M.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group><article-title>An overview of the effects of annexin 1 on cells involved in the inflammatory process</article-title><source>Mem. Inst. Oswaldo Cruz</source><year>2005</year><volume>100</volume><fpage>39</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1590/S0074-02762005000900008</pub-id><?supplied-pmid 15962097?><pub-id pub-id-type="pmid">15962097</pub-id></element-citation></ref><ref id="B56-ijms-19-01781"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufton</surname><given-names>N.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group><article-title>Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists</article-title><source>Pharmacol. Ther.</source><year>2010</year><volume>127</volume><fpage>175</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2010.04.010</pub-id><?supplied-pmid 20546777?><pub-id pub-id-type="pmid">20546777</pub-id></element-citation></ref><ref id="B57-ijms-19-01781"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayhoe</surname><given-names>R.P.G.</given-names></name><name><surname>Kamal</surname><given-names>A.M.</given-names></name><name><surname>Solito</surname><given-names>E.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Cooper</surname><given-names>D.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group><article-title>Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: Indication of distinct receptor involvement</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>2123</fpage><lpage>2130</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-08-3099</pub-id><?supplied-pmid 16278303?><pub-id pub-id-type="pmid">16278303</pub-id></element-citation></ref><ref id="B58-ijms-19-01781"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>S.</given-names></name><name><surname>Lange</surname><given-names>C.</given-names></name><name><surname>Wilbers</surname><given-names>A.</given-names></name><name><surname>Goebeler</surname><given-names>V.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>An annexin 1 N-terminal peptide activates leukocytes by triggering different members of the formyl peptide receptor family</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>7669</fpage><lpage>7676</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.12.7669</pub-id><?supplied-pmid 15187149?><pub-id pub-id-type="pmid">15187149</pub-id></element-citation></ref><ref id="B59-ijms-19-01781"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weyd</surname><given-names>H.</given-names></name></person-group><article-title>More than just innate affairs&#x02013;on the role of annexins in adaptive immunity</article-title><source>Biol. Chem.</source><year>2016</year><volume>397</volume><fpage>1017</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1515/hsz-2016-0191</pub-id><?supplied-pmid 27467753?><pub-id pub-id-type="pmid">27467753</pub-id></element-citation></ref><ref id="B60-ijms-19-01781"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>R.D.</given-names></name><name><surname>Boulay</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>J.M.</given-names></name><name><surname>Dahlgren</surname><given-names>C.</given-names></name><name><surname>Gerard</surname><given-names>C.</given-names></name><name><surname>Parmentier</surname><given-names>M.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name></person-group><article-title>International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family</article-title><source>Pharmacol. Rev.</source><year>2009</year><volume>61</volume><fpage>119</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1124/pr.109.001578</pub-id><?supplied-pmid 19498085?><pub-id pub-id-type="pmid">19498085</pub-id></element-citation></ref><ref id="B61-ijms-19-01781"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>Y.</given-names></name><name><surname>Murphy</surname><given-names>P.M.</given-names></name><name><surname>Wang</surname><given-names>J.M.</given-names></name></person-group><article-title>Formyl-peptide receptors revisited</article-title><source>Trends Immunol.</source><year>2002</year><volume>23</volume><fpage>541</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1016/S1471-4906(02)02316-5</pub-id><pub-id pub-id-type="pmid">12401407</pub-id></element-citation></ref><ref id="B62-ijms-19-01781"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Danielczyk</surname><given-names>A.</given-names></name><name><surname>Markoff</surname><given-names>A.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group><article-title>Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells</article-title><source>J. Immunol.</source><year>2002</year><volume>169</volume><fpage>1500</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.169.3.1500</pub-id><?supplied-pmid 12133977?><pub-id pub-id-type="pmid">12133977</pub-id></element-citation></ref><ref id="B63-ijms-19-01781"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>H.-Q.</given-names></name><name><surname>Ye</surname><given-names>R.</given-names></name></person-group><article-title>The Formyl Peptide Receptors: Diversity of Ligands and Mechanism for Recognition</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>455</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22030455</pub-id><?supplied-pmid 28335409?><pub-id pub-id-type="pmid">28335409</pub-id></element-citation></ref><ref id="B64-ijms-19-01781"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vong</surname><given-names>L.</given-names></name><name><surname>Ferraz</surname><given-names>J.G.P.</given-names></name><name><surname>Dufton</surname><given-names>N.</given-names></name><name><surname>Panaccione</surname><given-names>R.</given-names></name><name><surname>Beck</surname><given-names>P.L.</given-names></name><name><surname>Sherman</surname><given-names>P.M.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Wallace</surname><given-names>J.L.</given-names></name></person-group><article-title>Up-Regulation of Annexin-A1 and Lipoxin A 4 in Individuals with Ulcerative Colitis May Promote Mucosal Homeostasis</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e39244</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0039244</pub-id><?supplied-pmid 22723974?><pub-id pub-id-type="pmid">22723974</pub-id></element-citation></ref><ref id="B65-ijms-19-01781"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leoni</surname><given-names>G.</given-names></name><name><surname>Alam</surname><given-names>A.</given-names></name><name><surname>Neumann</surname><given-names>P.</given-names></name><name><surname>Lambeth</surname><given-names>J.D.</given-names></name><name><surname>Cheng</surname><given-names>G.</given-names></name><name><surname>McCoy</surname><given-names>J.</given-names></name><name><surname>Hilgarth</surname><given-names>R.S.</given-names></name><name><surname>Kundu</surname><given-names>K.</given-names></name><name><surname>Murthy</surname><given-names>N.</given-names></name><name><surname>Kusters</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Annexin A1, formyl peptide receptor, and NOX1 orchestrate epithelial repair</article-title><source>J. Clin. Invest.</source><year>2013</year><volume>123</volume><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1172/JCI65831</pub-id><?supplied-pmid 23241962?><pub-id pub-id-type="pmid">23241962</pub-id></element-citation></ref><ref id="B66-ijms-19-01781"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leoni</surname><given-names>G.</given-names></name><name><surname>Neumann</surname><given-names>P.A.</given-names></name><name><surname>Kamaly</surname><given-names>N.</given-names></name><name><surname>Quiros</surname><given-names>M.</given-names></name><name><surname>Nishio</surname><given-names>H.</given-names></name><name><surname>Jones</surname><given-names>H.R.</given-names></name><name><surname>Sumagin</surname><given-names>R.</given-names></name><name><surname>Hilgarth</surname><given-names>R.S.</given-names></name><name><surname>Alam</surname><given-names>A.</given-names></name><name><surname>Fredman</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Annexin A1-containing extracellular vesicles and polymeric nanoparticles promote epithelial wound repair</article-title><source>J. Clin. Invest.</source><year>2015</year><pub-id pub-id-type="doi">10.1172/JCI76693</pub-id><?supplied-pmid 25664854?><pub-id pub-id-type="pmid">25664854</pub-id></element-citation></ref><ref id="B67-ijms-19-01781"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ouyang</surname><given-names>N.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Nie</surname><given-names>T.</given-names></name><name><surname>Go</surname><given-names>M.F.</given-names></name><name><surname>Richards</surname><given-names>R.J.</given-names></name><name><surname>Rigas</surname><given-names>B.</given-names></name></person-group><article-title>MC-12, an Annexin A1-Based Peptide, Is Effective in the Treatment of Experimental Colitis</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e41585</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0041585</pub-id><?supplied-pmid 22844504?><pub-id pub-id-type="pmid">22844504</pub-id></element-citation></ref><ref id="B68-ijms-19-01781"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosicka</surname><given-names>A.</given-names></name><name><surname>Cunliffe</surname><given-names>A.D.</given-names></name><name><surname>Mackenzie</surname><given-names>R.</given-names></name><name><surname>Zariwala</surname><given-names>M.G.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Renshaw</surname><given-names>D.</given-names></name></person-group><article-title>Attenuation of plasma annexin A1 in human obesity</article-title><source>FASEB J.</source><year>2013</year><volume>27</volume><fpage>368</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1096/fj.12-213728</pub-id><?supplied-pmid 23038751?><pub-id pub-id-type="pmid">23038751</pub-id></element-citation></ref><ref id="B69-ijms-19-01781"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akasheh</surname><given-names>R.T.</given-names></name><name><surname>Pini</surname><given-names>M.</given-names></name><name><surname>Pang</surname><given-names>J.</given-names></name><name><surname>Fantuzzi</surname><given-names>G.</given-names></name></person-group><article-title>Increased adiposity in annexin A1-deficient mice</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e82608</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0082608</pub-id><?supplied-pmid 24312665?><pub-id pub-id-type="pmid">24312665</pub-id></element-citation></ref><ref id="B70-ijms-19-01781"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Jang</surname><given-names>J.</given-names></name><name><surname>Ghim</surname><given-names>J.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>P.</given-names></name><name><surname>Kwon</surname><given-names>Y.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Hwang</surname><given-names>D.</given-names></name><name><surname>Bae</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Proteomic analysis of the palmitate-induced myotube secretome reveals involvement of the annexin A1-formyl peptide receptor 2 (FPR2) pathway in insulin resistance</article-title><source>Mol. Cell. Proteom.</source><year>2015</year><volume>14</volume><fpage>882</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1074/mcp.M114.039651</pub-id><?supplied-pmid 25616869?><pub-id pub-id-type="pmid">25616869</pub-id></element-citation></ref><ref id="B71-ijms-19-01781"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheuk</surname><given-names>B.L.Y.</given-names></name><name><surname>Cheng</surname><given-names>S.W.K.</given-names></name></person-group><article-title>Annexin A1 expression in atherosclerotic carotid plaques and its relationship with plaque characteristics</article-title><source>Eur. J. Vasc. Endovasc. Surg.</source><year>2011</year><volume>41</volume><fpage>364</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2010.11.021</pub-id><?supplied-pmid 21195640?><pub-id pub-id-type="pmid">21195640</pub-id></element-citation></ref><ref id="B72-ijms-19-01781"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredman</surname><given-names>G.</given-names></name><name><surname>Hellmann</surname><given-names>J.</given-names></name><name><surname>Proto</surname><given-names>J.D.</given-names></name><name><surname>Kuriakose</surname><given-names>G.</given-names></name><name><surname>Colas</surname><given-names>R.A.</given-names></name><name><surname>Dorweiler</surname><given-names>B.</given-names></name><name><surname>Connolly</surname><given-names>E.S.</given-names></name><name><surname>Solomon</surname><given-names>R.</given-names></name><name><surname>Jones</surname><given-names>D.M.</given-names></name><name><surname>Heyer</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>12859</fpage><pub-id pub-id-type="doi">10.1038/ncomms12859</pub-id><?supplied-pmid 27659679?><pub-id pub-id-type="pmid">27659679</pub-id></element-citation></ref><ref id="B73-ijms-19-01781"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnamoorthy</surname><given-names>S.</given-names></name><name><surname>Recchiuti</surname><given-names>A.</given-names></name><name><surname>Chiang</surname><given-names>N.</given-names></name><name><surname>Fredman</surname><given-names>G.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs</article-title><source>Am. J. Pathol.</source><year>2012</year><volume>180</volume><fpage>2018</fpage><lpage>2027</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2012.01.028</pub-id><?supplied-pmid 22449948?><pub-id pub-id-type="pmid">22449948</pub-id></element-citation></ref><ref id="B74-ijms-19-01781"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solito</surname><given-names>E.</given-names></name><name><surname>McArthur</surname><given-names>S.</given-names></name><name><surname>Christian</surname><given-names>H.</given-names></name><name><surname>Gavins</surname><given-names>F.</given-names></name><name><surname>Buckingham</surname><given-names>J.C.</given-names></name><name><surname>Gillies</surname><given-names>G.E.</given-names></name></person-group><article-title>Annexin A1 in the brain&#x02014;Undiscovered roles?</article-title><source>Trends Pharmacol. Sci.</source><year>2008</year><volume>29</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2007.12.003</pub-id><?supplied-pmid 18262660?><pub-id pub-id-type="pmid">18262660</pub-id></element-citation></ref><ref id="B75-ijms-19-01781"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x000f6;rr</surname><given-names>A.</given-names></name><name><surname>Kress</surname><given-names>E.</given-names></name><name><surname>Podschun</surname><given-names>R.</given-names></name><name><surname>Pufe</surname><given-names>T.</given-names></name><name><surname>Tauber</surname><given-names>S.C.</given-names></name><name><surname>Brandenburg</surname><given-names>L.</given-names></name></person-group><article-title>Intrathecal application of the antimicrobial peptide CRAMP reduced mortality and neuroinflammation in an experimental model of pneumococcal meningitis</article-title><source>J. Infect.</source><year>2015</year><volume>71</volume><fpage>188</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2015.04.006</pub-id><?supplied-pmid 25896094?><pub-id pub-id-type="pmid">25896094</pub-id></element-citation></ref><ref id="B76-ijms-19-01781"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavins</surname><given-names>F.N.E.</given-names></name><name><surname>Dalli</surname><given-names>J.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Granger</surname><given-names>D.N.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group><article-title>Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation</article-title><source>FASEB J.</source><year>2007</year><volume>21</volume><fpage>1751</fpage><lpage>1758</lpage><pub-id pub-id-type="doi">10.1096/fj.06-7842com</pub-id><?supplied-pmid 17317721?><pub-id pub-id-type="pmid">17317721</pub-id></element-citation></ref><ref id="B77-ijms-19-01781"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vital</surname><given-names>S.A.</given-names></name><name><surname>Becker</surname><given-names>F.</given-names></name><name><surname>Holloway</surname><given-names>P.M.</given-names></name><name><surname>Russell</surname><given-names>J.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name><name><surname>Granger</surname><given-names>D.N.</given-names></name><name><surname>Gavins</surname><given-names>F.N.E.</given-names></name></person-group><article-title>Formyl-Peptide Receptor 2/3/Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease</article-title><source>Circulation</source><year>2016</year><volume>133</volume><fpage>2169</fpage><lpage>2179</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.115.020633</pub-id><?supplied-pmid 27154726?><pub-id pub-id-type="pmid">27154726</pub-id></element-citation></ref><ref id="B78-ijms-19-01781"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damazo</surname><given-names>A.S.</given-names></name><name><surname>Yona</surname><given-names>S.</given-names></name><name><surname>D&#x02019;Acquisto</surname><given-names>F.</given-names></name><name><surname>Flower</surname><given-names>R.J.</given-names></name><name><surname>Oliani</surname><given-names>S.M.</given-names></name><name><surname>Perretti</surname><given-names>M.</given-names></name></person-group><article-title>Critical protective role for annexin 1 gene expression in the endotoxemic murine microcirculation</article-title><source>Am. J. Pathol.</source><year>2005</year><volume>166</volume><fpage>1607</fpage><lpage>1617</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)62471-6</pub-id><pub-id pub-id-type="pmid">15920146</pub-id></element-citation></ref><ref id="B79-ijms-19-01781"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>I.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Hsu</surname><given-names>H.</given-names></name><name><surname>Shih</surname><given-names>C.</given-names></name></person-group><article-title>Serial Changes in Plasma Annexin A1 and Cortisol Levels in Sepsis Patients</article-title><source>Chin. J. Physiol.</source><year>2014</year><volume>57</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4077/CJP.2014.BAB193</pub-id><?supplied-pmid 24621333?><pub-id pub-id-type="pmid">24621333</pub-id></element-citation></ref><ref id="B80-ijms-19-01781"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>M.A.</given-names></name><name><surname>Heagy</surname><given-names>W.</given-names></name></person-group><article-title>Endotoxin tolerance: A review</article-title><source>Crit. Care Med.</source><year>2002</year><volume>30</volume><fpage>S64</fpage><lpage>S73</lpage><pub-id pub-id-type="doi">10.1097/00003246-200201001-00009</pub-id><?supplied-pmid 11891406?><pub-id pub-id-type="pmid">11891406</pub-id></element-citation></ref><ref id="B81-ijms-19-01781"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swisher</surname><given-names>J.F.A.</given-names></name><name><surname>Burton</surname><given-names>N.</given-names></name><name><surname>Bacot</surname><given-names>S.M.</given-names></name><name><surname>Vogel</surname><given-names>S.N.</given-names></name><name><surname>Feldman</surname><given-names>G.M.</given-names></name></person-group><article-title>Annexin A2 tetramer activates human and murine macrophages through TLR4</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-06-226944</pub-id><?supplied-pmid 19965653?><pub-id pub-id-type="pmid">19965653</pub-id></element-citation></ref><ref id="B82-ijms-19-01781"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swisher</surname><given-names>J.F.A.</given-names></name><name><surname>Khatri</surname><given-names>U.</given-names></name><name><surname>Feldman</surname><given-names>G.M.</given-names></name></person-group><article-title>Annexin A2 is a soluble mediator of macrophage activation</article-title><source>J. Leukoc. Biol.</source><year>2007</year><volume>82</volume><fpage>1174</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1189/jlb.0307154</pub-id><?supplied-pmid 17715360?><pub-id pub-id-type="pmid">17715360</pub-id></element-citation></ref><ref id="B83-ijms-19-01781"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Guo</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>G.</given-names></name><name><surname>Tan</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name></person-group><article-title>Annexin A2 binds to endosomes and negatively regulates TLR4-triggered inflammatory responses via the TRAM-TRIF pathway</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><fpage>15859</fpage><pub-id pub-id-type="doi">10.1038/srep15859</pub-id><?supplied-pmid 26527544?><pub-id pub-id-type="pmid">26527544</pub-id></element-citation></ref><ref id="B84-ijms-19-01781"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersen</surname><given-names>B.M.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Epstein</surname><given-names>A.L.</given-names></name><name><surname>Ohlfest</surname><given-names>J.R.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Blazar</surname><given-names>B.R.</given-names></name><name><surname>Pennell</surname><given-names>C.A.</given-names></name><name><surname>Olin</surname><given-names>M.R.</given-names></name></person-group><article-title>Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant</article-title><source>J. Immunother. Cancer</source><year>2016</year><volume>4</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1186/s40425-016-0112-6</pub-id><?supplied-pmid 26885373?><pub-id pub-id-type="pmid">26885373</pub-id></element-citation></ref><ref id="B85-ijms-19-01781"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seidah</surname><given-names>N.G.</given-names></name><name><surname>Poirier</surname><given-names>S.</given-names></name><name><surname>Denis</surname><given-names>M.</given-names></name><name><surname>Parker</surname><given-names>R.</given-names></name><name><surname>Miao</surname><given-names>B.</given-names></name><name><surname>Mapelli</surname><given-names>C.</given-names></name><name><surname>Prat</surname><given-names>A.</given-names></name><name><surname>Wassef</surname><given-names>H.</given-names></name><name><surname>Davignon</surname><given-names>J.</given-names></name><name><surname>Hajjar</surname><given-names>K.A.</given-names></name><etal/></person-group><article-title>Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e41865</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0041865</pub-id><?supplied-pmid 22848640?><pub-id pub-id-type="pmid">22848640</pub-id></element-citation></ref><ref id="B86-ijms-19-01781"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>K.</given-names></name><name><surname>Saavedra</surname><given-names>Y.G.L.</given-names></name><name><surname>Canuel</surname><given-names>M.</given-names></name><name><surname>Routhier</surname><given-names>S.</given-names></name><name><surname>Desjardins</surname><given-names>R.</given-names></name><name><surname>Hamelin</surname><given-names>J.</given-names></name><name><surname>Mayne</surname><given-names>J.</given-names></name><name><surname>Lazure</surname><given-names>C.</given-names></name><name><surname>Seidah</surname><given-names>N.G.</given-names></name><name><surname>Day</surname><given-names>R.</given-names></name></person-group><article-title>Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>17732</fpage><lpage>17746</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.541094</pub-id><?supplied-pmid 24808179?><pub-id pub-id-type="pmid">24808179</pub-id></element-citation></ref><ref id="B87-ijms-19-01781"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer</surname><given-names>G.</given-names></name><name><surname>Poirier</surname><given-names>S.</given-names></name><name><surname>Seidah</surname><given-names>N.G.</given-names></name></person-group><article-title>Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels</article-title><source>J. Biol. Chem.</source><year>2008</year><volume>283</volume><fpage>31791</fpage><lpage>31801</lpage><pub-id pub-id-type="doi">10.1074/jbc.M805971200</pub-id><?supplied-pmid 18799458?><pub-id pub-id-type="pmid">18799458</pub-id></element-citation></ref><ref id="B88-ijms-19-01781"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>S.</given-names></name><name><surname>Reddy</surname><given-names>S.V.</given-names></name><name><surname>Chirgwin</surname><given-names>J.M.</given-names></name><name><surname>Devlin</surname><given-names>R.</given-names></name><name><surname>Haipek</surname><given-names>C.</given-names></name><name><surname>Anderson</surname><given-names>J.</given-names></name><name><surname>Roodman</surname><given-names>G.D.</given-names></name></person-group><article-title>Cloning and identification of annexin II as an autocrine/paracrine factor that increases osteoclast formation and bone resorption</article-title><source>J. Biol. Chem.</source><year>1994</year><volume>269</volume><fpage>28696</fpage><lpage>28701</lpage><?supplied-pmid 7961821?><pub-id pub-id-type="pmid">7961821</pub-id></element-citation></ref><ref id="B89-ijms-19-01781"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Chung</surname><given-names>H.</given-names></name><name><surname>Reddy</surname><given-names>S.V.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Kurihara</surname><given-names>N.</given-names></name><name><surname>Zhao</surname><given-names>A.Z.</given-names></name><name><surname>Roodman</surname><given-names>G.D.</given-names></name></person-group><article-title>Annexin II Stimulates RANKL Expression Through MAPK</article-title><source>J. Bone Miner. Res.</source><year>2005</year><volume>20</volume><fpage>1161</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1359/JBMR.050207</pub-id><?supplied-pmid 15940368?><pub-id pub-id-type="pmid">15940368</pub-id></element-citation></ref><ref id="B90-ijms-19-01781"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Maeda</surname><given-names>H.</given-names></name><name><surname>Reddy</surname><given-names>S.V.</given-names></name><name><surname>Kurihara</surname><given-names>N.</given-names></name><name><surname>Leach</surname><given-names>R.</given-names></name><name><surname>Anderson</surname><given-names>J.L.</given-names></name><name><surname>Roodman</surname><given-names>G.D.</given-names></name></person-group><article-title>Cloning and characterization of the annexin II receptor on human marrow stromal cells</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>30542</fpage><lpage>30550</lpage><pub-id pub-id-type="doi">10.1074/jbc.M607072200</pub-id><?supplied-pmid 16895901?><pub-id pub-id-type="pmid">16895901</pub-id></element-citation></ref><ref id="B91-ijms-19-01781"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>S.</given-names></name><name><surname>Ranjan</surname><given-names>R.</given-names></name><name><surname>Pandey</surname><given-names>S.</given-names></name><name><surname>Mishra</surname><given-names>R.M.</given-names></name><name><surname>Seth</surname><given-names>T.</given-names></name><name><surname>Saxena</surname><given-names>R.</given-names></name></person-group><article-title>Effect of <italic>ANXA2</italic> gene single nucleotide polymorphism (SNP) on the development of osteonecrosis in Indian sickle cell patient: A PCR-RFLP approach</article-title><source>Indian J. Exp. Biol.</source><year>2012</year><volume>50</volume><fpage>455</fpage><lpage>458</lpage><?supplied-pmid 22822523?><pub-id pub-id-type="pmid">22822523</pub-id></element-citation></ref><ref id="B92-ijms-19-01781"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Souza</surname><given-names>S.</given-names></name><name><surname>Kurihara</surname><given-names>N.</given-names></name><name><surname>Shiozawa</surname><given-names>Y.</given-names></name><name><surname>Joseph</surname><given-names>J.</given-names></name><name><surname>Taichman</surname><given-names>R.</given-names></name><name><surname>Galson</surname><given-names>D.L.</given-names></name><name><surname>Roodman</surname><given-names>G.D.</given-names></name></person-group><article-title>Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>1888</fpage><lpage>1896</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-11-393348</pub-id><?supplied-pmid 22223826?><pub-id pub-id-type="pmid">22223826</pub-id></element-citation></ref><ref id="B93-ijms-19-01781"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perucci</surname><given-names>L.O.</given-names></name><name><surname>Sugimoto</surname><given-names>M.A.</given-names></name><name><surname>Gomes</surname><given-names>K.B.</given-names></name><name><surname>Dusse</surname><given-names>L.M.</given-names></name><name><surname>Teixeira</surname><given-names>M.M.</given-names></name><name><surname>Sousa</surname><given-names>L.P.</given-names></name></person-group><article-title>Annexin A1 and specialized proresolving lipid mediators: Promoting resolution as a therapeutic strategy in human inflammatory diseases</article-title><source>Expert Opin. Ther. Targets</source><year>2017</year><volume>21</volume><fpage>879</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1080/14728222.2017.1364363</pub-id><?supplied-pmid 28786708?><pub-id pub-id-type="pmid">28786708</pub-id></element-citation></ref><ref id="B94-ijms-19-01781"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiramoto</surname><given-names>H.</given-names></name><name><surname>Dansako</surname><given-names>H.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><name><surname>Satoh</surname><given-names>S.</given-names></name><name><surname>Wakita</surname><given-names>T.</given-names></name><name><surname>Ikeda</surname><given-names>M.</given-names></name><name><surname>Kato</surname><given-names>N.</given-names></name></person-group><article-title>Annexin A1 negatively regulates viral RNA replication of hepatitis C virus</article-title><source>Acta Med. Okayama</source><year>2015</year><volume>69</volume><fpage>71</fpage><lpage>78</lpage><?supplied-pmid 25899628?><pub-id pub-id-type="pmid">25899628</pub-id></element-citation></ref><ref id="B95-ijms-19-01781"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arora</surname><given-names>S.</given-names></name><name><surname>Lim</surname><given-names>W.</given-names></name><name><surname>Bist</surname><given-names>P.</given-names></name><name><surname>Perumalsamy</surname><given-names>R.</given-names></name><name><surname>Lukman</surname><given-names>H.M.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Welker</surname><given-names>L.B.</given-names></name><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Sethi</surname><given-names>G.</given-names></name><name><surname>Tambyah</surname><given-names>P.A.</given-names></name><etal/></person-group><article-title>Influenza A virus enhances its propagation through the modulation of Annexin-A1 dependent endosomal trafficking and apoptosis</article-title><source>Cell Death Differ.</source><year>2016</year><volume>23</volume><fpage>1243</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1038/cdd.2016.19</pub-id><?supplied-pmid 26943321?><pub-id pub-id-type="pmid">26943321</pub-id></element-citation></ref><ref id="B96-ijms-19-01781"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paudel</surname><given-names>N.</given-names></name><name><surname>Sadagopan</surname><given-names>S.</given-names></name><name><surname>Balasubramanian</surname><given-names>S.</given-names></name><name><surname>Chandran</surname><given-names>B.</given-names></name></person-group><article-title>Kaposi&#x02019;s Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen and Angiogenin Interact with Common Host Proteins, Including Annexin A2, Which Is Essential for Survival of Latently Infected Cells</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>1589</fpage><lpage>1607</lpage><pub-id pub-id-type="doi">10.1128/JVI.05754-11</pub-id><?supplied-pmid 22130534?><pub-id pub-id-type="pmid">22130534</pub-id></element-citation></ref><ref id="B97-ijms-19-01781"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W.</given-names></name><name><surname>Yan</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Yi</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Epstein-Barr virus latent membrane protein 1 mediates serine 25 phosphorylation and nuclear entry of annexin A2 via PI-PLC-PKC&#x003b1;/PKC&#x003b2; pathway</article-title><source>Mol. Carcinog.</source><year>2008</year><volume>47</volume><fpage>934</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1002/mc.20445</pub-id><?supplied-pmid 18412141?><pub-id pub-id-type="pmid">18412141</pub-id></element-citation></ref><ref id="B98-ijms-19-01781"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calmon</surname><given-names>M.F.</given-names></name><name><surname>Mota</surname><given-names>M.T.D.</given-names></name><name><surname>Babeto</surname><given-names>&#x000c9;.</given-names></name><name><surname>Candido</surname><given-names>N.M.</given-names></name><name><surname>Girol</surname><given-names>A.P.</given-names></name><name><surname>Mendiburu</surname><given-names>C.F.</given-names></name><name><surname>Bonilha</surname><given-names>J.L.</given-names></name><name><surname>Silvestre</surname><given-names>R.V.D.</given-names></name><name><surname>Rosa</surname><given-names>B.M.</given-names></name><name><surname>Thom&#x000e9;</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Overexpression of ANXA1 in Penile Carcinomas Positive for High-Risk HPVs</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e53260</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0053260</pub-id><?supplied-pmid 23341933?><pub-id pub-id-type="pmid">23341933</pub-id></element-citation></ref><ref id="B99-ijms-19-01781"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Kornfeld</surname><given-names>H.</given-names></name><name><surname>Remold</surname><given-names>H.G.</given-names></name></person-group><article-title>Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence</article-title><source>Nat. Immunol.</source><year>2008</year><volume>9</volume><fpage>1189</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1038/ni.1654</pub-id><?supplied-pmid 18794848?><pub-id pub-id-type="pmid">18794848</pub-id></element-citation></ref><ref id="B100-ijms-19-01781"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rong</surname><given-names>B.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Ming</surname><given-names>Z.</given-names></name><name><surname>Cai</surname><given-names>X.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name></person-group><article-title>Elevated serum annexin A1 as potential diagnostic marker for lung cancer: A retrospective case-control study</article-title><source>Am. J. Transl. Res.</source><year>2014</year><volume>6</volume><fpage>558</fpage><lpage>569</lpage><?supplied-pmid 25360220?><pub-id pub-id-type="pmid">25360220</pub-id></element-citation></ref><ref id="B101-ijms-19-01781"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voigt</surname><given-names>T.</given-names></name><name><surname>Sebald</surname><given-names>H.</given-names></name><name><surname>Schoenauer</surname><given-names>R.</given-names></name><name><surname>Levano</surname><given-names>S.</given-names></name><name><surname>Girard</surname><given-names>T.</given-names></name><name><surname>Hoppeler</surname><given-names>H.H.</given-names></name><name><surname>Babiychuk</surname><given-names>E.B.</given-names></name><name><surname>Draeger</surname><given-names>A.</given-names></name></person-group><article-title>Annexin A1 is a biomarker of T-tubular repair in skeletal muscle of nonmyopathic patients undergoing statin therapy</article-title><source>FASEB J.</source><year>2013</year><volume>27</volume><fpage>2156</fpage><lpage>2164</lpage><pub-id pub-id-type="doi">10.1096/fj.12-219345</pub-id><?supplied-pmid 23413360?><pub-id pub-id-type="pmid">23413360</pub-id></element-citation></ref><ref id="B102-ijms-19-01781"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>S.</given-names></name><name><surname>Xie</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name></person-group><article-title>Annexin A2 is an independent prognostic biomarker for evaluating the malignant progression of laryngeal cancer</article-title><source>Exp. Ther. Med.</source><year>2017</year><volume>14</volume><fpage>6113</fpage><lpage>6118</lpage><pub-id pub-id-type="doi">10.3892/etm.2017.5298</pub-id><?supplied-pmid 29285166?><pub-id pub-id-type="pmid">29285166</pub-id></element-citation></ref><ref id="B103-ijms-19-01781"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><name><surname>Peng</surname><given-names>S.</given-names></name><name><surname>Jeng</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>H.</given-names></name><name><surname>Lai</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Hsu</surname><given-names>H.</given-names></name></person-group><article-title>Down-Regulation of Annexin A10 in Hepatocellular Carcinoma Is Associated with Vascular Invasion, Early Recurrence, and Poor Prognosis in Synergy with p53 Mutation</article-title><source>Am. J. Pathol.</source><year>2002</year><volume>160</volume><fpage>1831</fpage><lpage>1837</lpage><pub-id pub-id-type="doi">10.1016/S0002-9440(10)61129-7</pub-id><pub-id pub-id-type="pmid">12000734</pub-id></element-citation></ref><ref id="B104-ijms-19-01781"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Yuan</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Hsu</surname><given-names>H.</given-names></name><name><surname>Jeng</surname><given-names>Y.</given-names></name></person-group><article-title>Annexin A10 is an immunohistochemical marker for adenocarcinoma of the upper gastrointestinal tract and pancreatobiliary system</article-title><source>Histopathology</source><year>2013</year><volume>63</volume><fpage>640</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1111/his.12229</pub-id><?supplied-pmid 24024557?><pub-id pub-id-type="pmid">24024557</pub-id></element-citation></ref><ref id="B105-ijms-19-01781"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>M.I.</given-names></name><name><surname>Singh</surname><given-names>J.</given-names></name><name><surname>Niknami</surname><given-names>M.</given-names></name><name><surname>Kurek</surname><given-names>C.</given-names></name><name><surname>Yao</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Maclean</surname><given-names>F.</given-names></name><name><surname>King</surname><given-names>N.J.C.</given-names></name><name><surname>Gelb</surname><given-names>M.H.</given-names></name><name><surname>Scott</surname><given-names>K.F.</given-names></name><etal/></person-group><article-title>Cytosolic phospholipase A2-&#x003b1;: A potential therapeutic target for prostate cancer</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>8070</fpage><lpage>8079</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0566</pub-id><?supplied-pmid 19088022?><pub-id pub-id-type="pmid">19088022</pub-id></element-citation></ref><ref id="B106-ijms-19-01781"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.W.</given-names></name><name><surname>Rhee</surname><given-names>H.J.</given-names></name><name><surname>Ko</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>Y.J.</given-names></name><name><surname>Kim</surname><given-names>H.G.</given-names></name><name><surname>Yang</surname><given-names>J.M.</given-names></name><name><surname>Choi</surname><given-names>E.C.</given-names></name><name><surname>Na</surname><given-names>D.S.</given-names></name></person-group><article-title>Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site</article-title><source>J. Biol. Chem.</source><year>2001</year><volume>276</volume><fpage>15712</fpage><lpage>15719</lpage><pub-id pub-id-type="doi">10.1074/jbc.M009905200</pub-id><?supplied-pmid 11278580?><pub-id pub-id-type="pmid">11278580</pub-id></element-citation></ref><ref id="B107-ijms-19-01781"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Ko</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Choi</surname><given-names>E.C.</given-names></name><name><surname>Na</surname><given-names>D.S.</given-names></name></person-group><article-title>Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: Specific interaction model</article-title><source>FEBS Lett.</source><year>2001</year><volume>489</volume><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)02326-7</pub-id><pub-id pub-id-type="pmid">11165258</pub-id></element-citation></ref><ref id="B108-ijms-19-01781"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K.M.</given-names></name><name><surname>Kim</surname><given-names>D.K.</given-names></name><name><surname>Park</surname><given-names>Y.M.</given-names></name><name><surname>Kim</surname><given-names>C.K.</given-names></name><name><surname>Na</surname><given-names>D.S.</given-names></name></person-group><article-title>Annexin-I inhibits phospholipase A2 by specific interaction, not by substrate depletion</article-title><source>FEBS Lett.</source><year>1994</year><volume>343</volume><fpage>251</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/0014-5793(94)80566-0</pub-id><pub-id pub-id-type="pmid">8174710</pub-id></element-citation></ref><ref id="B109-ijms-19-01781"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van de Graaf</surname><given-names>S.F.J.</given-names></name><name><surname>Hoenderop</surname><given-names>J.G.J.</given-names></name><name><surname>Gkika</surname><given-names>D.</given-names></name><name><surname>Lamers</surname><given-names>D.</given-names></name><name><surname>Prenen</surname><given-names>J.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Staub</surname><given-names>O.</given-names></name><name><surname>Nilius</surname><given-names>B.</given-names></name><name><surname>Bindels</surname><given-names>R.J.M.</given-names></name></person-group><article-title>Functional expression of the epithelial Ca<sup>2+</sup> channels (TRPV5 and TRPV6) requires association of the S100A10-annexin 2 complex</article-title><source>EMBO J.</source><year>2003</year><volume>22</volume><fpage>1478</fpage><lpage>1487</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg162</pub-id><?supplied-pmid 12660155?><pub-id pub-id-type="pmid">12660155</pub-id></element-citation></ref><ref id="B110-ijms-19-01781"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donier</surname><given-names>E.</given-names></name><name><surname>Rugiero</surname><given-names>F.</given-names></name><name><surname>Okuse</surname><given-names>K.</given-names></name><name><surname>Wood</surname><given-names>J.N.</given-names></name></person-group><article-title>Annexin II Light Chain p11 Promotes Functional Expression of Acid-sensing Ion Channel ASIC1a</article-title><source>J. Biol. Chem.</source><year>2005</year><volume>280</volume><fpage>38666</fpage><lpage>38672</lpage><pub-id pub-id-type="doi">10.1074/jbc.M505981200</pub-id><?supplied-pmid 16169854?><pub-id pub-id-type="pmid">16169854</pub-id></element-citation></ref><ref id="B111-ijms-19-01781"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girard</surname><given-names>C.</given-names></name><name><surname>Tinel</surname><given-names>N.</given-names></name><name><surname>Terrenoire</surname><given-names>C.</given-names></name><name><surname>Romey</surname><given-names>G.</given-names></name><name><surname>Lazdunski</surname><given-names>M.</given-names></name><name><surname>Borsotto</surname><given-names>M.</given-names></name></person-group><article-title>p11, an annexin II subunit, an auxiliary protein associated with the background K<sup>+</sup> channel, TASK-1</article-title><source>EMBO J.</source><year>2002</year><volume>21</volume><fpage>4439</fpage><lpage>4448</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdf469</pub-id><?supplied-pmid 12198146?><pub-id pub-id-type="pmid">12198146</pub-id></element-citation></ref><ref id="B112-ijms-19-01781"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muimo</surname><given-names>R.</given-names></name></person-group><article-title>Regulation of CFTR function by annexin A2-S100A10 complex in health and disease</article-title><source>Gen. Physiol. Biophys.</source><year>2009</year><volume>28</volume><fpage>14</fpage><lpage>19</lpage></element-citation></ref><ref id="B113-ijms-19-01781"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hessner</surname><given-names>F.</given-names></name><name><surname>Dlugos</surname><given-names>C.P.</given-names></name><name><surname>Chehab</surname><given-names>T.</given-names></name><name><surname>Schaefer</surname><given-names>C.</given-names></name><name><surname>Homey</surname><given-names>B.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Weide</surname><given-names>T.</given-names></name><name><surname>Pavenst&#x000e4;dt</surname><given-names>H.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>CC chemokine receptor 10 cell surface presentation in melanocytes is regulated by the novel interaction partner S100A10</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>22649</fpage><pub-id pub-id-type="doi">10.1038/srep22649</pub-id><?supplied-pmid 26941067?><pub-id pub-id-type="pmid">26941067</pub-id></element-citation></ref><ref id="B114-ijms-19-01781"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svenningsson</surname><given-names>P.</given-names></name><name><surname>Chergui</surname><given-names>K.</given-names></name><name><surname>Rachleff</surname><given-names>I.</given-names></name><name><surname>Flajolet</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>el Yacoubi</surname><given-names>M.</given-names></name><name><surname>Vaugeois</surname><given-names>J.</given-names></name><name><surname>Nomikos</surname><given-names>G.G.</given-names></name><name><surname>Greengard</surname><given-names>P.</given-names></name></person-group><article-title>Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States</article-title><source>Science</source><year>2006</year><volume>311</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1126/science.1117571</pub-id><?supplied-pmid 16400147?><pub-id pub-id-type="pmid">16400147</pub-id></element-citation></ref><ref id="B115-ijms-19-01781"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grewal</surname><given-names>T.</given-names></name><name><surname>Hoque</surname><given-names>M.</given-names></name><name><surname>Conway</surname><given-names>J.R.W.</given-names></name><name><surname>Reverter</surname><given-names>M.</given-names></name><name><surname>Wahba</surname><given-names>M.</given-names></name><name><surname>Beevi</surname><given-names>S.S.</given-names></name><name><surname>Timpson</surname><given-names>P.</given-names></name><name><surname>Enrich</surname><given-names>C.</given-names></name><name><surname>Rentero</surname><given-names>C.</given-names></name></person-group><article-title>Annexin A6-A multifunctional scaffold in cell motility</article-title><source>Cell Adh. Migr.</source><year>2017</year><volume>11</volume><fpage>288</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1080/19336918.2016.1268318</pub-id><?supplied-pmid 28060548?><pub-id pub-id-type="pmid">28060548</pub-id></element-citation></ref><ref id="B116-ijms-19-01781"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitzig</surname><given-names>N.</given-names></name><name><surname>Brinkmann</surname><given-names>B.F.</given-names></name><name><surname>Koerdt</surname><given-names>S.N.</given-names></name><name><surname>Rosso</surname><given-names>G.</given-names></name><name><surname>Shahin</surname><given-names>V.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>Annexin A8 promotes VEGF-A driven endothelial cell sprouting</article-title><source>Cell Adh. Migr.</source><year>2017</year><volume>11</volume><fpage>275</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1080/19336918.2016.1264559</pub-id><?supplied-pmid 28060564?><pub-id pub-id-type="pmid">28060564</pub-id></element-citation></ref><ref id="B117-ijms-19-01781"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poeter</surname><given-names>M.</given-names></name><name><surname>Radke</surname><given-names>S.</given-names></name><name><surname>Koese</surname><given-names>M.</given-names></name><name><surname>Hessner</surname><given-names>F.</given-names></name><name><surname>Hegemann</surname><given-names>A.</given-names></name><name><surname>Musiol</surname><given-names>A.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Grewal</surname><given-names>T.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>Disruption of the annexin A1/S100A11 complex increases the migration and clonogenic growth by dysregulating epithelial growth factor (EGF) signaling</article-title><source>Biochim. Biophys. Acta</source><year>2013</year><volume>1833</volume><fpage>1700</fpage><lpage>1711</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.12.006</pub-id><?supplied-pmid 23246849?><pub-id pub-id-type="pmid">23246849</pub-id></element-citation></ref><ref id="B118-ijms-19-01781"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tatenhorst</surname><given-names>L.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Paulus</surname><given-names>W.</given-names></name></person-group><article-title>Knockdown of annexin 2 decreases migration of human glioma cells in vitro</article-title><source>Neuropathol. Appl. Neurobiol.</source><year>2006</year><volume>32</volume><fpage>271</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2006.00720.x</pub-id><?supplied-pmid 16640645?><pub-id pub-id-type="pmid">16640645</pub-id></element-citation></ref><ref id="B119-ijms-19-01781"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Ludwig</surname><given-names>C.</given-names></name><name><surname>Konietzko</surname><given-names>V.</given-names></name><name><surname>Kharitonenkov</surname><given-names>A.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group><article-title>Tyrosine phosphorylation of annexin A2 regulates Rho-mediated actin rearrangement and cell adhesion</article-title><source>J. Cell Sci.</source><year>2008</year><volume>121</volume><fpage>2177</fpage><lpage>2185</lpage><pub-id pub-id-type="doi">10.1242/jcs.028415</pub-id><?supplied-pmid 18565825?><pub-id pub-id-type="pmid">18565825</pub-id></element-citation></ref><ref id="B120-ijms-19-01781"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quiskamp</surname><given-names>N.</given-names></name><name><surname>Poeter</surname><given-names>M.</given-names></name><name><surname>Raabe</surname><given-names>C.A.</given-names></name><name><surname>Hohenester</surname><given-names>U.M.</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>S.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>The tumor suppressor annexin A10 is a novel component of nuclear paraspeckles</article-title><source>Cell. Mol. Life Sci.</source><year>2014</year><volume>71</volume><fpage>311</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1007/s00018-013-1375-4</pub-id><?supplied-pmid 23715859?><pub-id pub-id-type="pmid">23715859</pub-id></element-citation></ref><ref id="B121-ijms-19-01781"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>R.</given-names></name><name><surname>Campbell</surname><given-names>K.P.</given-names></name></person-group><article-title>Dysferlin and muscle membrane repair</article-title><source>Curr. Opin. Cell Biol.</source><year>2007</year><volume>19</volume><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2007.07.001</pub-id><?supplied-pmid 17662592?><pub-id pub-id-type="pmid">17662592</pub-id></element-citation></ref><ref id="B122-ijms-19-01781"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draeger</surname><given-names>A.</given-names></name><name><surname>Monastyrskaya</surname><given-names>K.</given-names></name><name><surname>Babiychuk</surname><given-names>E.B.</given-names></name></person-group><article-title>Plasma membrane repair and cellular damage control: The annexin survival kit</article-title><source>Biochem. Pharmacol.</source><year>2011</year><volume>81</volume><fpage>703</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2010.12.027</pub-id><?supplied-pmid 21219882?><pub-id pub-id-type="pmid">21219882</pub-id></element-citation></ref><ref id="B123-ijms-19-01781"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauritzen</surname><given-names>S.P.</given-names></name><name><surname>Boye</surname><given-names>T.L.</given-names></name><name><surname>Nylandsted</surname><given-names>J.</given-names></name></person-group><article-title>Annexins are instrumental for efficient plasma membrane repair in cancer cells</article-title><source>Semin. Cell Dev. Biol.</source><year>2015</year><volume>45</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2015.10.028</pub-id><?supplied-pmid 26498035?><pub-id pub-id-type="pmid">26498035</pub-id></element-citation></ref><ref id="B124-ijms-19-01781"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>S.T.</given-names></name><name><surname>McNeil</surname><given-names>P.L.</given-names></name></person-group><article-title>Membrane Repair: Mechanisms and Pathophysiology</article-title><source>Physiol. Rev.</source><year>2015</year><volume>95</volume><fpage>1205</fpage><lpage>1240</lpage><pub-id pub-id-type="doi">10.1152/physrev.00037.2014</pub-id><?supplied-pmid 26336031?><pub-id pub-id-type="pmid">26336031</pub-id></element-citation></ref><ref id="B125-ijms-19-01781"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koerdt</surname><given-names>S.N.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group><article-title>Annexin A2 is involved in Ca<sup>2+</sup>-dependent plasma membrane repair in primary human endothelial cells</article-title><source>Biochim. Biophys. Acta</source><year>2017</year><volume>1864</volume><fpage>1046</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2016.12.007</pub-id><?supplied-pmid 27956131?><pub-id pub-id-type="pmid">27956131</pub-id></element-citation></ref><ref id="B126-ijms-19-01781"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demonbreun</surname><given-names>A.R.</given-names></name><name><surname>Quattrocelli</surname><given-names>M.</given-names></name><name><surname>Barefield</surname><given-names>D.Y.</given-names></name><name><surname>Allen</surname><given-names>M.V.</given-names></name><name><surname>Swanson</surname><given-names>K.E.</given-names></name><name><surname>McNally</surname><given-names>E.M.</given-names></name></person-group><article-title>An actin-dependent annexin complex mediates plasma membrane repair in muscle</article-title><source>J. Cell Biol.</source><year>2016</year><volume>213</volume><fpage>705</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1083/jcb.201512022</pub-id><?supplied-pmid 27298325?><pub-id pub-id-type="pmid">27298325</pub-id></element-citation></ref><ref id="B127-ijms-19-01781"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swaggart</surname><given-names>K.A.</given-names></name><name><surname>Demonbreun</surname><given-names>A.R.</given-names></name><name><surname>Vo</surname><given-names>A.H.</given-names></name><name><surname>Swanson</surname><given-names>K.E.</given-names></name><name><surname>Kim</surname><given-names>E.Y.</given-names></name><name><surname>Fahrenbach</surname><given-names>J.P.</given-names></name><name><surname>Holley-Cuthrell</surname><given-names>J.</given-names></name><name><surname>Eskin</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Squire</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>6004</fpage><lpage>6009</lpage><pub-id pub-id-type="doi">10.1073/pnas.1324242111</pub-id><?supplied-pmid 24717843?><pub-id pub-id-type="pmid">24717843</pub-id></element-citation></ref><ref id="B128-ijms-19-01781"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boye</surname><given-names>T.L.</given-names></name><name><surname>Nylandsted</surname><given-names>J.</given-names></name></person-group><article-title>Annexins in plasma membrane repair</article-title><source>Biol. Chem.</source><year>2016</year><volume>397</volume><fpage>961</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1515/hsz-2016-0171</pub-id><?supplied-pmid 27341560?><pub-id pub-id-type="pmid">27341560</pub-id></element-citation></ref><ref id="B129-ijms-19-01781"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linero</surname><given-names>F.N.</given-names></name><name><surname>Sep&#x000fa;lveda</surname><given-names>C.S.</given-names></name><name><surname>Giovannoni</surname><given-names>F.</given-names></name><name><surname>Castilla</surname><given-names>V.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>C.C.</given-names></name><name><surname>Scolaro</surname><given-names>L.A.</given-names></name><name><surname>Damonte</surname><given-names>E.B.</given-names></name></person-group><article-title>Host cell factors as antiviral targets in arenavirus infection</article-title><source>Viruses</source><year>2012</year><volume>4</volume><fpage>1569</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.3390/v4091569</pub-id><?supplied-pmid 23170173?><pub-id pub-id-type="pmid">23170173</pub-id></element-citation></ref><ref id="B130-ijms-19-01781"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DaMatta</surname><given-names>R.A.</given-names></name><name><surname>Seabra</surname><given-names>S.H.</given-names></name><name><surname>Deolindo</surname><given-names>P.</given-names></name><name><surname>Arnholdt</surname><given-names>A.C.V.</given-names></name><name><surname>Manh&#x000e3;es</surname><given-names>L.</given-names></name><name><surname>Goldenberg</surname><given-names>S.</given-names></name><name><surname>de Souza</surname><given-names>W.</given-names></name></person-group><article-title><italic>Trypanosoma cruzi</italic> exposes phosphatidylserine as an evasion mechanism</article-title><source>FEMS Microbiol. Lett.</source><year>2007</year><volume>266</volume><fpage>29</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6968.2006.00495.x</pub-id><?supplied-pmid 17092297?><pub-id pub-id-type="pmid">17092297</pub-id></element-citation></ref><ref id="B131-ijms-19-01781"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seabra</surname><given-names>S.H.</given-names></name><name><surname>de Souza</surname><given-names>W.</given-names></name><name><surname>DaMatta</surname><given-names>R.A.</given-names></name></person-group><article-title>Toxoplasma gondii exposes phosphatidylserine inducing a TGF-&#x003b2;1 autocrine effect orchestrating macrophage evasion</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2004</year><volume>324</volume><fpage>744</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.09.114</pub-id><?supplied-pmid 15474490?><pub-id pub-id-type="pmid">15474490</pub-id></element-citation></ref><ref id="B132-ijms-19-01781"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farias</surname><given-names>L.H.S.</given-names></name><name><surname>Rodrigues</surname><given-names>A.P.D.</given-names></name><name><surname>Silveira</surname><given-names>F.T.</given-names></name><name><surname>Seabra</surname><given-names>S.H.</given-names></name><name><surname>DaMatta</surname><given-names>R.A.</given-names></name><name><surname>Saraiva</surname><given-names>E.M.</given-names></name><name><surname>Silva</surname><given-names>E.O.</given-names></name></person-group><article-title>Phosphatidylserine Exposure and Surface Sugars in Two <italic>Leishmania (Viannia) braziliensis</italic> Strains Involved in Cutaneous and Mucocutaneous Leishmaniasis</article-title><source>J. Infect. Dis.</source><year>2013</year><volume>207</volume><fpage>537</fpage><lpage>543</lpage><pub-id pub-id-type="doi">10.1093/infdis/jis689</pub-id><?supplied-pmid 23148292?><pub-id pub-id-type="pmid">23148292</pub-id></element-citation></ref><ref id="B133-ijms-19-01781"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>M.L.</given-names></name><name><surname>Stone</surname><given-names>K.L.</given-names></name><name><surname>Colangelo</surname><given-names>C.M.</given-names></name><name><surname>Gulcicek</surname><given-names>E.E.</given-names></name><name><surname>Palese</surname><given-names>P.</given-names></name></person-group><article-title>Cellular Proteins in Influenza Virus Particles</article-title><source>PLoS Pathog.</source><year>2008</year><volume>4</volume><elocation-id>e1000085</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1000085</pub-id><?supplied-pmid 18535660?><pub-id pub-id-type="pmid">18535660</pub-id></element-citation></ref><ref id="B134-ijms-19-01781"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loret</surname><given-names>S.</given-names></name><name><surname>Guay</surname><given-names>G.</given-names></name><name><surname>Lipp&#x000e9;</surname><given-names>R.</given-names></name></person-group><article-title>Comprehensive characterization of extracellular herpes simplex virus type 1 virions</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>8605</fpage><lpage>8618</lpage><pub-id pub-id-type="doi">10.1128/JVI.00904-08</pub-id><?supplied-pmid 18596102?><pub-id pub-id-type="pmid">18596102</pub-id></element-citation></ref><ref id="B135-ijms-19-01781"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dry</surname><given-names>I.</given-names></name><name><surname>Haig</surname><given-names>D.M.</given-names></name><name><surname>Inglis</surname><given-names>N.F.</given-names></name><name><surname>Imrie</surname><given-names>L.</given-names></name><name><surname>Stewart</surname><given-names>J.P.</given-names></name><name><surname>Russell</surname><given-names>G.C.</given-names></name></person-group><article-title>Proteomic analysis of pathogenic and attenuated alcelaphine herpesvirus 1</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>5390</fpage><lpage>5397</lpage><pub-id pub-id-type="doi">10.1128/JVI.00094-08</pub-id><?supplied-pmid 18353942?><pub-id pub-id-type="pmid">18353942</pub-id></element-citation></ref><ref id="B136-ijms-19-01781"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidick</surname><given-names>S.</given-names></name><name><surname>Leroy</surname><given-names>B.</given-names></name><name><surname>Palmeira</surname><given-names>L.</given-names></name><name><surname>Machiels</surname><given-names>B.</given-names></name><name><surname>Mast</surname><given-names>J.</given-names></name><name><surname>Fran&#x000e7;ois</surname><given-names>S.</given-names></name><name><surname>Wattiez</surname><given-names>R.</given-names></name><name><surname>Vanderplasschen</surname><given-names>A.</given-names></name><name><surname>Gillet</surname><given-names>L.</given-names></name></person-group><article-title>Proteomic Characterization of Murid Herpesvirus 4 Extracellular Virions</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e83842</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0083842</pub-id><?supplied-pmid 24386290?><pub-id pub-id-type="pmid">24386290</pub-id></element-citation></ref><ref id="B137-ijms-19-01781"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kattenhorn</surname><given-names>L.M.</given-names></name><name><surname>Mills</surname><given-names>R.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name><name><surname>Lomsadze</surname><given-names>A.</given-names></name><name><surname>Makeev</surname><given-names>V.</given-names></name><name><surname>Borodovsky</surname><given-names>M.</given-names></name><name><surname>Ploegh</surname><given-names>H.L.</given-names></name><name><surname>Kessler</surname><given-names>B.M.</given-names></name></person-group><article-title>Identification of Proteins Associated with Murine Cytomegalovirus Virions</article-title><source>J. Virol.</source><year>2004</year><volume>78</volume><fpage>11187</fpage><lpage>11197</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.20.11187-11197.2004</pub-id><?supplied-pmid 15452238?><pub-id pub-id-type="pmid">15452238</pub-id></element-citation></ref><ref id="B138-ijms-19-01781"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chertova</surname><given-names>E.</given-names></name><name><surname>Chertov</surname><given-names>O.</given-names></name><name><surname>Coren</surname><given-names>L.V.</given-names></name><name><surname>Roser</surname><given-names>J.D.</given-names></name><name><surname>Trubey</surname><given-names>C.M.</given-names></name><name><surname>Bess</surname><given-names>J.W.</given-names></name><name><surname>Sowder</surname><given-names>R.C.</given-names></name><name><surname>Barsov</surname><given-names>E.</given-names></name><name><surname>Hood</surname><given-names>B.L.</given-names></name><name><surname>Fisher</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Proteomic and Biochemical Analysis of Purified Human Immunodeficiency Virus Type 1 Produced from Infected Monocyte-Derived Macrophages</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>9039</fpage><lpage>9052</lpage><pub-id pub-id-type="doi">10.1128/JVI.01013-06</pub-id><?supplied-pmid 16940516?><pub-id pub-id-type="pmid">16940516</pub-id></element-citation></ref><ref id="B139-ijms-19-01781"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moerdyk-Schauwecker</surname><given-names>M.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Grdzelishvili</surname><given-names>V.Z.</given-names></name></person-group><article-title>Analysis of virion associated host proteins in vesicular stomatitis virus using a proteomics approach</article-title><source>Virol. J.</source><year>2009</year><volume>6</volume><fpage>166</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-6-166</pub-id><?supplied-pmid 19821998?><pub-id pub-id-type="pmid">19821998</pub-id></element-citation></ref><ref id="B140-ijms-19-01781"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moerdyk-Schauwecker</surname><given-names>M.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Grdzelishvili</surname><given-names>V.Z.</given-names></name></person-group><article-title>Cellular Proteins Associated with the Interior and Exterior of Vesicular Stomatitis Virus Virions</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e104688</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0104688</pub-id><?supplied-pmid 25105980?><pub-id pub-id-type="pmid">25105980</pub-id></element-citation></ref><ref id="B141-ijms-19-01781"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuss</surname><given-names>J.E.</given-names></name><name><surname>Kehn-Hall</surname><given-names>K.</given-names></name><name><surname>Benedict</surname><given-names>A.</given-names></name><name><surname>Costantino</surname><given-names>J.</given-names></name><name><surname>Ward</surname><given-names>M.</given-names></name><name><surname>Peyser</surname><given-names>B.D.</given-names></name><name><surname>Retterer</surname><given-names>C.J.</given-names></name><name><surname>Tressler</surname><given-names>L.E.</given-names></name><name><surname>Wanner</surname><given-names>L.M.</given-names></name><name><surname>McGovern</surname><given-names>H.F.</given-names></name><etal/></person-group><article-title>Multi-faceted proteomic characterization of host protein complement of Rift Valley fever virus virions and identification of specific heat shock proteins, including HSP90, as important viral host factors</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e93483</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0093483</pub-id><?supplied-pmid 24809507?><pub-id pub-id-type="pmid">24809507</pub-id></element-citation></ref><ref id="B142-ijms-19-01781"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tcherniuk</surname><given-names>S.</given-names></name><name><surname>Cenac</surname><given-names>N.</given-names></name><name><surname>Comte</surname><given-names>M.</given-names></name><name><surname>Frouard</surname><given-names>J.</given-names></name><name><surname>Errazuriz-Cerda</surname><given-names>E.</given-names></name><name><surname>Galabov</surname><given-names>A.</given-names></name><name><surname>Morange</surname><given-names>P.</given-names></name><name><surname>Vergnolle</surname><given-names>N.</given-names></name><name><surname>Si-Tahar</surname><given-names>M.</given-names></name><name><surname>Alessi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Formyl Peptide Receptor 2 Plays a Deleterious Role During Influenza A Virus Infections</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>214</volume><fpage>237</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw127</pub-id><?supplied-pmid 27034344?><pub-id pub-id-type="pmid">27034344</pub-id></element-citation></ref><ref id="B143-ijms-19-01781"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alessi</surname><given-names>M.</given-names></name><name><surname>Cenac</surname><given-names>N.</given-names></name><name><surname>Si-Tahar</surname><given-names>M.</given-names></name><name><surname>Riteau</surname><given-names>B.</given-names></name></person-group><article-title>FPR2: A Novel Promising Target for the Treatment of Influenza</article-title><source>Front. Microbiol.</source><year>2017</year><volume>8</volume><fpage>1719</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2017.01719</pub-id><?supplied-pmid 28928730?><pub-id pub-id-type="pmid">28928730</pub-id></element-citation></ref><ref id="B144-ijms-19-01781"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gershom</surname><given-names>E.S.</given-names></name><name><surname>Hoek</surname><given-names>A.L.V.</given-names></name><name><surname>Meixner</surname><given-names>S.C.</given-names></name><name><surname>Sutherland</surname><given-names>M.R.</given-names></name><name><surname>Pryzdial</surname><given-names>E.L.G.</given-names></name></person-group><article-title>Herpesviruses enhance fibrin clot lysis</article-title><source>Thromb. Haemost.</source><year>2012</year><volume>107</volume><fpage>760</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1160/TH11-08-0601</pub-id><?supplied-pmid 22318336?><pub-id pub-id-type="pmid">22318336</pub-id></element-citation></ref><ref id="B145-ijms-19-01781"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeBouder</surname><given-names>F.</given-names></name><name><surname>Lina</surname><given-names>B.</given-names></name><name><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name><name><surname>Riteau</surname><given-names>B.</given-names></name></person-group><article-title>Plasminogen promotes influenza A virus replication through an annexin 2-dependent pathway in the absence of neuraminidase</article-title><source>J. Gen. Virol.</source><year>2010</year><volume>91</volume><fpage>2753</fpage><lpage>2761</lpage><pub-id pub-id-type="doi">10.1099/vir.0.023804-0</pub-id><?supplied-pmid 20702651?><pub-id pub-id-type="pmid">20702651</pub-id></element-citation></ref><ref id="B146-ijms-19-01781"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeBouder</surname><given-names>F.</given-names></name><name><surname>Morello</surname><given-names>E.</given-names></name><name><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name><name><surname>Bosse</surname><given-names>F.</given-names></name><name><surname>P&#x000e9;choux</surname><given-names>C.</given-names></name><name><surname>Delmas</surname><given-names>B.</given-names></name><name><surname>Riteau</surname><given-names>B.</given-names></name></person-group><article-title>Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>6820</fpage><lpage>6828</lpage><pub-id pub-id-type="doi">10.1128/JVI.00246-08</pub-id><?supplied-pmid 18448517?><pub-id pub-id-type="pmid">18448517</pub-id></element-citation></ref><ref id="B147-ijms-19-01781"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Jin</surname><given-names>M.</given-names></name></person-group><article-title>Identification of human host proteins contributing to H5N1 influenza virus propagation by membrane proteomics</article-title><source>J. Proteome Res.</source><year>2012</year><volume>11</volume><fpage>5396</fpage><lpage>5405</lpage><pub-id pub-id-type="doi">10.1021/pr3006342</pub-id><?supplied-pmid 22985253?><pub-id pub-id-type="pmid">22985253</pub-id></element-citation></ref><ref id="B148-ijms-19-01781"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berri</surname><given-names>F.</given-names></name><name><surname>Haffar</surname><given-names>G.</given-names></name><name><surname>Le</surname><given-names>V.B.</given-names></name><name><surname>Sadewasser</surname><given-names>A.</given-names></name><name><surname>Paki</surname><given-names>K.</given-names></name><name><surname>Lina</surname><given-names>B.</given-names></name><name><surname>Wolff</surname><given-names>T.</given-names></name><name><surname>Riteau</surname><given-names>B.</given-names></name></person-group><article-title>Annexin V Incorporated into Influenza Virus Particles Inhibits Gamma Interferon Signaling and Promotes Viral Replication</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>11215</fpage><lpage>11228</lpage><pub-id pub-id-type="doi">10.1128/JVI.01405-14</pub-id><?supplied-pmid 25031344?><pub-id pub-id-type="pmid">25031344</pub-id></element-citation></ref><ref id="B149-ijms-19-01781"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hertogs</surname><given-names>K.</given-names></name><name><surname>Leenders</surname><given-names>W.P.</given-names></name><name><surname>Depla</surname><given-names>E.</given-names></name><name><surname>de Bruin</surname><given-names>W.C.</given-names></name><name><surname>Meheus</surname><given-names>L.</given-names></name><name><surname>Raymackers</surname><given-names>J.</given-names></name><name><surname>Moshage</surname><given-names>H.</given-names></name><name><surname>Yap</surname><given-names>S.H.</given-names></name></person-group><article-title>Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein</article-title><source>Virology</source><year>1993</year><volume>197</volume><fpage>549</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1006/viro.1993.1628</pub-id><?supplied-pmid 8249278?><pub-id pub-id-type="pmid">8249278</pub-id></element-citation></ref><ref id="B150-ijms-19-01781"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neurath</surname><given-names>A.R.</given-names></name><name><surname>Strick</surname><given-names>N.</given-names></name></person-group><article-title>The putative cell receptors for hepatitis B virus (HBV), annexin V, and apolipoprotein H, bind to lipid components of HBV</article-title><source>Virology</source><year>1994</year><volume>204</volume><fpage>475</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1006/viro.1994.1558</pub-id><?supplied-pmid 8091682?><pub-id pub-id-type="pmid">8091682</pub-id></element-citation></ref><ref id="B151-ijms-19-01781"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Meyer</surname><given-names>S.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name><name><surname>Depla</surname><given-names>E.</given-names></name><name><surname>Maertens</surname><given-names>G.</given-names></name><name><surname>Yap</surname><given-names>S.H.</given-names></name></person-group><article-title>Involvement of phosphatidylserine and non-phospholipid components of the hepatitis B virus envelope in human Annexin V binding and in HBV infection in vitro</article-title><source>J. Hepatol.</source><year>1999</year><volume>31</volume><fpage>783</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/S0168-8278(99)80278-5</pub-id><pub-id pub-id-type="pmid">10580574</pub-id></element-citation></ref><ref id="B152-ijms-19-01781"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Meyer</surname><given-names>S.</given-names></name><name><surname>Gong</surname><given-names>Z.J.</given-names></name><name><surname>Hertogs</surname><given-names>K.</given-names></name><name><surname>Depla</surname><given-names>E.</given-names></name><name><surname>van Pelt</surname><given-names>J.F.</given-names></name><name><surname>Roskams</surname><given-names>T.</given-names></name><name><surname>Maertens</surname><given-names>G.</given-names></name><name><surname>Yap</surname><given-names>S.H.</given-names></name></person-group><article-title>Influence of the administration of human annexin V on in vitro binding of small hepatitis B surface antigen to human and to rat hepatocytes and on in vitro hepatitis B virus infection</article-title><source>J. Viral Hepat.</source><year>2000</year><volume>7</volume><fpage>104</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2893.2000.00207.x</pub-id><?supplied-pmid 10760040?><pub-id pub-id-type="pmid">10760040</pub-id></element-citation></ref><ref id="B153-ijms-19-01781"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Z.J.</given-names></name><name><surname>de Meyer</surname><given-names>S.</given-names></name><name><surname>van Pelt</surname><given-names>J.</given-names></name><name><surname>Hertogs</surname><given-names>K.</given-names></name><name><surname>Depla</surname><given-names>E.</given-names></name><name><surname>Soumillion</surname><given-names>A.</given-names></name><name><surname>Fevery</surname><given-names>J.</given-names></name><name><surname>Yap</surname><given-names>S.H.</given-names></name></person-group><article-title>Transfection of a rat hepatoma cell line with a construct expressing human liver annexin V confers susceptibility to hepatitis B virus infection</article-title><source>Hepatology</source><year>1999</year><volume>29</volume><fpage>576</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1002/hep.510290238</pub-id><?supplied-pmid 9918938?><pub-id pub-id-type="pmid">9918938</pub-id></element-citation></ref><ref id="B154-ijms-19-01781"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Meyer</surname><given-names>S.</given-names></name><name><surname>Depla</surname><given-names>E.</given-names></name><name><surname>Maertens</surname><given-names>G.</given-names></name><name><surname>Soumillion</surname><given-names>A.</given-names></name><name><surname>Yap</surname><given-names>S.H.</given-names></name></person-group><article-title>Characterization of small hepatitis B surface antigen epitopes involved in binding to human annexin V</article-title><source>J. Viral Hepat.</source><year>1999</year><volume>6</volume><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2893.1999.00167.x</pub-id><?supplied-pmid 10607242?><pub-id pub-id-type="pmid">10607242</pub-id></element-citation></ref><ref id="B155-ijms-19-01781"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodham</surname><given-names>A.W.</given-names></name><name><surname>da Silva</surname><given-names>D.M.</given-names></name><name><surname>Skeate</surname><given-names>J.G.</given-names></name><name><surname>Raff</surname><given-names>A.B.</given-names></name><name><surname>Ambroso</surname><given-names>M.R.</given-names></name><name><surname>Brand</surname><given-names>H.E.</given-names></name><name><surname>Isas</surname><given-names>J.M.</given-names></name><name><surname>Langen</surname><given-names>R.</given-names></name><name><surname>Kast</surname><given-names>W.M.</given-names></name></person-group><article-title>The S100A10 subunit of the annexin A2 heterotetramer facilitates L2-mediated human papillomavirus infection</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e43519</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0043519</pub-id><?supplied-pmid 22927980?><pub-id pub-id-type="pmid">22927980</pub-id></element-citation></ref><ref id="B156-ijms-19-01781"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dziduszko</surname><given-names>A.</given-names></name><name><surname>Ozbun</surname><given-names>M.A.</given-names></name></person-group><article-title>Annexin A2 and S100A10 regulate human papillomavirus type 16 entry and intracellular trafficking in human keratinocytes</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>7502</fpage><lpage>7515</lpage><pub-id pub-id-type="doi">10.1128/JVI.00519-13</pub-id><pub-id pub-id-type="pmid">23637395</pub-id></element-citation></ref><ref id="B157-ijms-19-01781"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodham</surname><given-names>A.W.</given-names></name><name><surname>Taylor</surname><given-names>J.R.</given-names></name><name><surname>Jimenez</surname><given-names>A.I.</given-names></name><name><surname>Skeate</surname><given-names>J.G.</given-names></name><name><surname>Schmidt</surname><given-names>T.</given-names></name><name><surname>Brand</surname><given-names>H.E.</given-names></name><name><surname>da Silva</surname><given-names>D.M.</given-names></name><name><surname>Kast</surname><given-names>W.M.</given-names></name></person-group><article-title>Small molecule inhibitors of the annexin A2 heterotetramer prevent human papillomavirus type 16 infection</article-title><source>J. Antimicrob. Chemother.</source><year>2015</year><volume>70</volume><fpage>1686</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.1093/jac/dkv045</pub-id><?supplied-pmid 25712315?><pub-id pub-id-type="pmid">25712315</pub-id></element-citation></ref><ref id="B158-ijms-19-01781"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietropaolo</surname><given-names>R.L.</given-names></name><name><surname>Compton</surname><given-names>T.</given-names></name></person-group><article-title>Direct interaction between human cytomegalovirus glycoprotein B and cellular annexin II</article-title><source>J. Virol.</source><year>1997</year><volume>71</volume><fpage>9803</fpage><lpage>9807</lpage><?supplied-pmid 9371650?><pub-id pub-id-type="pmid">9371650</pub-id></element-citation></ref><ref id="B159-ijms-19-01781"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bold</surname><given-names>S.</given-names></name><name><surname>Ohlin</surname><given-names>M.</given-names></name><name><surname>Garten</surname><given-names>W.</given-names></name><name><surname>Radsak</surname><given-names>K.</given-names></name></person-group><article-title>Structural domains involved in human cytomegalovirus glycoprotein B-mediated cell-cell fusion</article-title><source>J. Gen. Virol.</source><year>1996</year><volume>77</volume><fpage>2297</fpage><lpage>2302</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-77-9-2297</pub-id><?supplied-pmid 8811030?><pub-id pub-id-type="pmid">8811030</pub-id></element-citation></ref><ref id="B160-ijms-19-01781"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Derry</surname><given-names>M.C.</given-names></name><name><surname>Sutherland</surname><given-names>M.R.</given-names></name><name><surname>Restall</surname><given-names>C.M.</given-names></name><name><surname>Waisman</surname><given-names>D.M.</given-names></name><name><surname>Pryzdial</surname><given-names>E.L.G.</given-names></name></person-group><article-title>Annexin 2-mediated enhancement of cytomegalovirus infection opposes inhibition by annexin 1 or annexin 5</article-title><source>J. Gen. Virol.</source><year>2007</year><volume>88</volume><fpage>19</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1099/vir.0.82294-0</pub-id><?supplied-pmid 17170432?><pub-id pub-id-type="pmid">17170432</pub-id></element-citation></ref><ref id="B161-ijms-19-01781"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez-Reyes</surname><given-names>S.</given-names></name><name><surname>Garc&#x000ed;a-Manso</surname><given-names>A.</given-names></name><name><surname>del Barrio</surname><given-names>G.</given-names></name><name><surname>Dalton</surname><given-names>K.P.</given-names></name><name><surname>Gonz&#x000e1;lez-Molleda</surname><given-names>L.</given-names></name><name><surname>Arrojo-Fern&#x000e1;ndez</surname><given-names>J.</given-names></name><name><surname>Nicieza</surname><given-names>I.</given-names></name><name><surname>Parra</surname><given-names>F.</given-names></name></person-group><article-title>Role of annexin A2 in cellular entry of rabbit vesivirus</article-title><source>J. Gen. Virol.</source><year>2009</year><volume>90</volume><fpage>2724</fpage><lpage>2730</lpage><pub-id pub-id-type="doi">10.1099/vir.0.013276-0</pub-id><?supplied-pmid 19605586?><pub-id pub-id-type="pmid">19605586</pub-id></element-citation></ref><ref id="B162-ijms-19-01781"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>R.</given-names></name><name><surname>Ward</surname><given-names>M.</given-names></name><name><surname>Bright</surname><given-names>H.</given-names></name><name><surname>Priest</surname><given-names>R.</given-names></name><name><surname>Foster</surname><given-names>M.R.</given-names></name><name><surname>Hurle</surname><given-names>M.</given-names></name><name><surname>Blair</surname><given-names>E.</given-names></name><name><surname>Bird</surname><given-names>M.</given-names></name></person-group><article-title>Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells</article-title><source>Microbes Infect.</source><year>2003</year><volume>5</volume><fpage>123</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(02)00079-5</pub-id><pub-id pub-id-type="pmid">12650770</pub-id></element-citation></ref><ref id="B163-ijms-19-01781"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Chou</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Ho</surname><given-names>M.</given-names></name></person-group><article-title>Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>11809</fpage><lpage>11820</lpage><pub-id pub-id-type="doi">10.1128/JVI.00297-11</pub-id><?supplied-pmid 21900167?><pub-id pub-id-type="pmid">21900167</pub-id></element-citation></ref><ref id="B164-ijms-19-01781"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirschnek</surname><given-names>S.</given-names></name><name><surname>Adams</surname><given-names>C.</given-names></name><name><surname>Gulbins</surname><given-names>E.</given-names></name></person-group><article-title>Annexin II is a novel receptor for Pseudomonas aeruginosa</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2005</year><volume>327</volume><fpage>900</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.12.089</pub-id><?supplied-pmid 15649430?><pub-id pub-id-type="pmid">15649430</pub-id></element-citation></ref><ref id="B165-ijms-19-01781"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Shou</surname><given-names>C.</given-names></name></person-group><article-title>N-Terminal Polypeptide of Annexin A2 Decreases Infection of Mycoplasma hyorhinis to Gastric Cancer Cells</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0147776</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0147776</pub-id><?supplied-pmid 26812398?><pub-id pub-id-type="pmid">26812398</pub-id></element-citation></ref><ref id="B166-ijms-19-01781"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Somarajan</surname><given-names>S.R.</given-names></name><name><surname>Al-Asadi</surname><given-names>F.</given-names></name><name><surname>Ramasamy</surname><given-names>K.</given-names></name><name><surname>Pandranki</surname><given-names>L.</given-names></name><name><surname>Baseman</surname><given-names>J.B.</given-names></name><name><surname>Kannan</surname><given-names>T.R.</given-names></name></person-group><article-title>Annexin A2 mediates Mycoplasma pneumoniae community-acquired respiratory distress syndrome toxin binding to eukaryotic cells</article-title><source>MBio</source><year>2014</year><volume>5</volume><pub-id pub-id-type="doi">10.1128/mBio.01497-14</pub-id><?supplied-pmid 25139904?><pub-id pub-id-type="pmid">25139904</pub-id></element-citation></ref><ref id="B167-ijms-19-01781"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ham</surname><given-names>H.</given-names></name><name><surname>Sreelatha</surname><given-names>A.</given-names></name><name><surname>Orth</surname><given-names>K.</given-names></name></person-group><article-title>Manipulation of host membranes by bacterial effectors</article-title><source>Nat. Rev. Microbiol.</source><year>2011</year><volume>9</volume><fpage>635</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2602</pub-id><?supplied-pmid 21765451?><pub-id pub-id-type="pmid">21765451</pub-id></element-citation></ref><ref id="B168-ijms-19-01781"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potez</surname><given-names>S.</given-names></name><name><surname>Luginb&#x000fc;hl</surname><given-names>M.</given-names></name><name><surname>Monastyrskaya</surname><given-names>K.</given-names></name><name><surname>Hostettler</surname><given-names>A.</given-names></name><name><surname>Draeger</surname><given-names>A.</given-names></name><name><surname>Babiychuk</surname><given-names>E.B.</given-names></name></person-group><article-title>Tailored protection against plasmalemmal injury by annexins with different Ca<sup>2+</sup> sensitivities</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>17982</fpage><lpage>17991</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.187625</pub-id><?supplied-pmid 21454475?><pub-id pub-id-type="pmid">21454475</pub-id></element-citation></ref><ref id="B169-ijms-19-01781"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babiychuk</surname><given-names>E.B.</given-names></name><name><surname>Monastyrskaya</surname><given-names>K.</given-names></name><name><surname>Potez</surname><given-names>S.</given-names></name><name><surname>Draeger</surname><given-names>A.</given-names></name></person-group><article-title>Blebbing confers resistance against cell lysis</article-title><source>Cell Death Differ.</source><year>2011</year><volume>18</volume><fpage>80</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/cdd.2010.81</pub-id><?supplied-pmid 20596076?><pub-id pub-id-type="pmid">20596076</pub-id></element-citation></ref><ref id="B170-ijms-19-01781"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>B.D.</given-names></name><name><surname>Neill</surname><given-names>D.R.</given-names></name><name><surname>Becker</surname><given-names>K.A.</given-names></name><name><surname>Gore</surname><given-names>S.</given-names></name><name><surname>Bricio-Moreno</surname><given-names>L.</given-names></name><name><surname>Ziobro</surname><given-names>R.</given-names></name><name><surname>Edwards</surname><given-names>M.J.</given-names></name><name><surname>M&#x000fc;hlemann</surname><given-names>K.</given-names></name><name><surname>Steinmann</surname><given-names>J.</given-names></name><name><surname>Kleuser</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice</article-title><source>Nat. Biotechnol.</source><year>2015</year><volume>33</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/nbt.3037</pub-id><?supplied-pmid 25362245?><pub-id pub-id-type="pmid">25362245</pub-id></element-citation></ref><ref id="B171-ijms-19-01781"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luisoni</surname><given-names>S.</given-names></name><name><surname>Suomalainen</surname><given-names>M.</given-names></name><name><surname>Boucke</surname><given-names>K.</given-names></name><name><surname>Tanner</surname><given-names>L.B.</given-names></name><name><surname>Wenk</surname><given-names>M.R.</given-names></name><name><surname>Guan</surname><given-names>X.L.</given-names></name><name><surname>Grzybek</surname><given-names>M.</given-names></name><name><surname>Coskun</surname><given-names>&#x000dc;.</given-names></name><name><surname>Greber</surname><given-names>U.F.</given-names></name></person-group><article-title>Co-option of Membrane Wounding Enables Virus Penetration into Cells</article-title><source>Cell Host Microbe</source><year>2015</year><volume>18</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.06.006</pub-id><?supplied-pmid 26159720?><pub-id pub-id-type="pmid">26159720</pub-id></element-citation></ref><ref id="B172-ijms-19-01781"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>D.</given-names></name><name><surname>Liston</surname><given-names>D.R.</given-names></name><name><surname>Idone</surname><given-names>V.J.</given-names></name><name><surname>Di</surname><given-names>A.</given-names></name><name><surname>Nelson</surname><given-names>D.J.</given-names></name><name><surname>Pujol</surname><given-names>C.</given-names></name><name><surname>Bliska</surname><given-names>J.B.</given-names></name><name><surname>Chakrabarti</surname><given-names>S.</given-names></name><name><surname>Andrews</surname><given-names>N.W.</given-names></name></person-group><article-title>A Process for Controlling Intracellular Bacterial Infections Induced by Membrane Injury</article-title><source>Science</source><year>2004</year><volume>304</volume><fpage>1515</fpage><lpage>1518</lpage><pub-id pub-id-type="doi">10.1126/science.1098371</pub-id><?supplied-pmid 15178804?><pub-id pub-id-type="pmid">15178804</pub-id></element-citation></ref><ref id="B173-ijms-19-01781"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poeter</surname><given-names>M.</given-names></name><name><surname>Brandherm</surname><given-names>I.</given-names></name><name><surname>Rossaint</surname><given-names>J.</given-names></name><name><surname>Rosso</surname><given-names>G.</given-names></name><name><surname>Shahin</surname><given-names>V.</given-names></name><name><surname>Skryabin</surname><given-names>B.V.</given-names></name><name><surname>Zarbock</surname><given-names>A.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>Annexin A8 controls leukocyte recruitment to activated endothelial cells via cell surface delivery of CD63</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3738</fpage><pub-id pub-id-type="doi">10.1038/ncomms4738</pub-id><?supplied-pmid 24769558?><pub-id pub-id-type="pmid">24769558</pub-id></element-citation></ref><ref id="B174-ijms-19-01781"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandherm</surname><given-names>I.</given-names></name><name><surname>Disse</surname><given-names>J.</given-names></name><name><surname>Zeuschner</surname><given-names>D.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name></person-group><article-title>cAMP-induced secretion of endothelial von Willebrand factor is regulated by a phosphorylation/dephosphorylation switch in annexin A2</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>1042</fpage><lpage>1051</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-12-475251</pub-id><?supplied-pmid 23757730?><pub-id pub-id-type="pmid">23757730</pub-id></element-citation></ref><ref id="B175-ijms-19-01781"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musiol</surname><given-names>A.</given-names></name><name><surname>Gran</surname><given-names>S.</given-names></name><name><surname>Ehrhardt</surname><given-names>C.</given-names></name><name><surname>Ludwig</surname><given-names>S.</given-names></name><name><surname>Grewal</surname><given-names>T.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name></person-group><article-title>Annexin A6-balanced late endosomal cholesterol controls influenza A replication and propagation</article-title><source>MBio</source><year>2013</year><volume>4</volume><fpage>e00608-13</fpage><pub-id pub-id-type="doi">10.1128/mBio.00608-13</pub-id><?supplied-pmid 24194536?><pub-id pub-id-type="pmid">24194536</pub-id></element-citation></ref><ref id="B176-ijms-19-01781"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backes</surname><given-names>P.</given-names></name><name><surname>Quinkert</surname><given-names>D.</given-names></name><name><surname>Reiss</surname><given-names>S.</given-names></name><name><surname>Binder</surname><given-names>M.</given-names></name><name><surname>Zayas</surname><given-names>M.</given-names></name><name><surname>Rescher</surname><given-names>U.</given-names></name><name><surname>Gerke</surname><given-names>V.</given-names></name><name><surname>Bartenschlager</surname><given-names>R.</given-names></name><name><surname>Lohmann</surname><given-names>V.</given-names></name></person-group><article-title>Role of annexin A2 in the production of infectious hepatitis C virus particles</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>5775</fpage><lpage>5789</lpage><pub-id pub-id-type="doi">10.1128/JVI.02343-09</pub-id><?supplied-pmid 20335258?><pub-id pub-id-type="pmid">20335258</pub-id></element-citation></ref><ref id="B177-ijms-19-01781"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>V.</given-names></name><name><surname>Lai</surname><given-names>C.</given-names></name><name><surname>Chao</surname><given-names>T.</given-names></name><name><surname>Jeng</surname><given-names>K.</given-names></name><name><surname>Lai</surname><given-names>M.M.C.</given-names></name></person-group><article-title>Annexin A2 Is Involved in the Formation of Hepatitis C Virus Replication Complex on the Lipid Raft</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>4139</fpage><lpage>4150</lpage><pub-id pub-id-type="doi">10.1128/JVI.06327-11</pub-id><?supplied-pmid 22301157?><pub-id pub-id-type="pmid">22301157</pub-id></element-citation></ref><ref id="B178-ijms-19-01781"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C.</given-names></name><name><surname>Jeng</surname><given-names>K.</given-names></name><name><surname>Machida</surname><given-names>K.</given-names></name><name><surname>Lai</surname><given-names>M.M.C.</given-names></name></person-group><article-title>Association of hepatitis C virus replication complexes with microtubules and actin filaments is dependent on the interaction of NS3 and NS5A</article-title><source>J. Virol.</source><year>2008</year><volume>82</volume><fpage>8838</fpage><lpage>8848</lpage><pub-id pub-id-type="doi">10.1128/JVI.00398-08</pub-id><?supplied-pmid 18562541?><pub-id pub-id-type="pmid">18562541</pub-id></element-citation></ref><ref id="B179-ijms-19-01781"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>R&#x000f6;sch</surname><given-names>K.</given-names></name><name><surname>Kwiatkowski</surname><given-names>M.</given-names></name><name><surname>Hofmann</surname><given-names>S.</given-names></name><name><surname>Sch&#x000f6;bel</surname><given-names>A.</given-names></name><name><surname>Gr&#x000fc;ttner</surname><given-names>C.</given-names></name><name><surname>Wurlitzer</surname><given-names>M.</given-names></name><name><surname>Schl&#x000fc;ter</surname><given-names>H.</given-names></name><name><surname>Herker</surname><given-names>E.</given-names></name></person-group><article-title>Quantitative Lipid Droplet Proteome Analysis Identifies Annexin A3 as a Cofactor for HCV Particle Production</article-title><source>Cell Rep.</source><year>2016</year><volume>16</volume><fpage>3219</fpage><lpage>3231</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.052</pub-id><?supplied-pmid 27653686?><pub-id pub-id-type="pmid">27653686</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-19-01781-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Overview of diseases associated with changes in annexin expression levels. Abbreviation: T2D: Type 2 diabetes mellitus [<xref rid="B93-ijms-19-01781" ref-type="bibr">93</xref>]; APS: antiphospholipid syndrome [<xref rid="B43-ijms-19-01781" ref-type="bibr">43</xref>]; APL: promyelocytic leukemia [<xref rid="B50-ijms-19-01781" ref-type="bibr">50</xref>]; HCV: hepatitis C virus [<xref rid="B94-ijms-19-01781" ref-type="bibr">94</xref>]; IAV: influenza A virus [<xref rid="B95-ijms-19-01781" ref-type="bibr">95</xref>]; KSHV: Kaposi&#x02019;s sarcoma-associated herpesvirus [<xref rid="B96-ijms-19-01781" ref-type="bibr">96</xref>]; EBV: Epstein-Barr-Virus [<xref rid="B97-ijms-19-01781" ref-type="bibr">97</xref>]; HPV: <italic>Human papillomavirus</italic> [<xref rid="B98-ijms-19-01781" ref-type="bibr">98</xref>]; <italic>M. tuberculosis</italic>: <italic>Mycobacterium tuberculosis</italic> [<xref rid="B99-ijms-19-01781" ref-type="bibr">99</xref>].</p></caption><graphic xlink:href="ijms-19-01781-g001"/></fig></floats-group></article>